1
|
Ahmed SR, Befano B, Lemay A, Egemen D, Rodriguez AC, Angara S, Desai K, Jeronimo J, Antani S, Campos N, Inturrisi F, Perkins R, Kreimer A, Wentzensen N, Herrero R, Del Pino M, Quint W, de Sanjose S, Schiffman M, Kalpathy-Cramer J. Reproducible and clinically translatable deep neural networks for cervical screening. Sci Rep 2023; 13:21772. [PMID: 38066031 PMCID: PMC10709439 DOI: 10.1038/s41598-023-48721-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Accepted: 11/29/2023] [Indexed: 12/18/2023] Open
Abstract
Cervical cancer is a leading cause of cancer mortality, with approximately 90% of the 250,000 deaths per year occurring in low- and middle-income countries (LMIC). Secondary prevention with cervical screening involves detecting and treating precursor lesions; however, scaling screening efforts in LMIC has been hampered by infrastructure and cost constraints. Recent work has supported the development of an artificial intelligence (AI) pipeline on digital images of the cervix to achieve an accurate and reliable diagnosis of treatable precancerous lesions. In particular, WHO guidelines emphasize visual triage of women testing positive for human papillomavirus (HPV) as the primary screen, and AI could assist in this triage task. In this work, we implemented a comprehensive deep-learning model selection and optimization study on a large, collated, multi-geography, multi-institution, and multi-device dataset of 9462 women (17,013 images). We evaluated relative portability, repeatability, and classification performance. The top performing model, when combined with HPV type, achieved an area under the Receiver Operating Characteristics (ROC) curve (AUC) of 0.89 within our study population of interest, and a limited total extreme misclassification rate of 3.4%, on held-aside test sets. Our model also produced reliable and consistent predictions, achieving a strong quadratic weighted kappa (QWK) of 0.86 and a minimal %2-class disagreement (% 2-Cl. D.) of 0.69%, between image pairs across women. Our work is among the first efforts at designing a robust, repeatable, accurate and clinically translatable deep-learning model for cervical screening.
Collapse
Affiliation(s)
- Syed Rakin Ahmed
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, 02129, USA.
- Harvard Graduate Program in Biophysics, Harvard Medical School, Harvard University, Cambridge, MA, 02115, USA.
- Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
- Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, 03755, USA.
| | - Brian Befano
- Information Management Services, Calverton, MD, 20705, USA
- University of Washington, Seattle, WA, 98195, USA
| | - Andreanne Lemay
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, 02129, USA
- NeuroPoly, Polytechnique Montreal, Montreal, QC, H3T 1N8, Canada
| | - Didem Egemen
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Ana Cecilia Rodriguez
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Sandeep Angara
- Computational Health Research Branch, National Library of Medicine, Lister Hill Center, Bethesda, MD, 20894, USA
| | - Kanan Desai
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Jose Jeronimo
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Sameer Antani
- Computational Health Research Branch, National Library of Medicine, Lister Hill Center, Bethesda, MD, 20894, USA
| | - Nicole Campos
- Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA
| | - Federica Inturrisi
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Rebecca Perkins
- Department of Obstetrics & Gynecology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA
| | - Aimee Kreimer
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Nicolas Wentzensen
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Rolando Herrero
- Agencia Costarricense de Investigaciones Biomedicas (ACIB), Fundacion INCIENSA, San Jose, Costa Rica
| | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | - Silvia de Sanjose
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
- ISGlobal, Barcelona, Spain
| | - Mark Schiffman
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Jayashree Kalpathy-Cramer
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, 02129, USA
- Department of Ophthalmology, University of Colorado Anschutz, Denver, CO, 80045, USA
| |
Collapse
|
2
|
Wiesinger M, Stuhlmann F, Bohman M, Micke P, Will C, Yildiz H, Abbass F, Arndt BP, Devlin JA, Erlewein S, Fleck M, Jäger JI, Latacz BM, Schweitzer D, Umbrazunas G, Wursten E, Blaum K, Matsuda Y, Mooser A, Quint W, Soter A, Walz J, Smorra C, Ulmer S. Trap-integrated fluorescence detection with silicon photomultipliers for sympathetic laser cooling in a cryogenic Penning trap. Rev Sci Instrum 2023; 94:123202. [PMID: 38109470 DOI: 10.1063/5.0170629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 11/23/2023] [Indexed: 12/20/2023]
Abstract
We present a fluorescence-detection system for laser-cooled 9Be+ ions based on silicon photomultipliers (SiPMs) operated at 4 K and integrated into our cryogenic 1.9 T multi-Penning-trap system. Our approach enables fluorescence detection in a hermetically sealed cryogenic Penning-trap chamber with limited optical access, where state-of-the-art detection using a telescope and photomultipliers at room temperature would be extremely difficult. We characterize the properties of the SiPM in a cryocooler at 4 K, where we measure a dark count rate below 1 s-1 and a detection efficiency of 2.5(3)%. We further discuss the design of our cryogenic fluorescence-detection trap and analyze the performance of our detection system by fluorescence spectroscopy of 9Be+ ion clouds during several runs of our sympathetic laser-cooling experiment.
Collapse
Affiliation(s)
- M Wiesinger
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - F Stuhlmann
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - M Bohman
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - P Micke
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
| | - C Will
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - H Yildiz
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - F Abbass
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - B P Arndt
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J A Devlin
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Erlewein
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Fleck
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Graduate School of Arts and Sciences, University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo 153-8902, Japan
| | - J I Jäger
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - B M Latacz
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D Schweitzer
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - G Umbrazunas
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Eidgenössische Technische Hochschule Zürich, John-von-Neumann-Weg 9, 8093 Zürich, Switzerland
| | - E Wursten
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - Y Matsuda
- Graduate School of Arts and Sciences, University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo 153-8902, Japan
| | - A Mooser
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - A Soter
- Eidgenössische Technische Hochschule Zürich, John-von-Neumann-Weg 9, 8093 Zürich, Switzerland
| | - J Walz
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
- Helmholtz-Institut Mainz, Staudingerweg 18, 55128 Mainz, Germany
| | - C Smorra
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Ulmer
- RIKEN, Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany
| |
Collapse
|
3
|
Klimes JW, Kanika, Krishnan A, Reich B, Anjum KK, Baus P, Birkl G, Quint W, Schott W, Vogel M. Cryogenic vacuum valve with actuation times down to 50 ms. Rev Sci Instrum 2023; 94:113202. [PMID: 37975747 DOI: 10.1063/5.0158043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Accepted: 10/29/2023] [Indexed: 11/19/2023]
Abstract
We have conceived, built, and operated a cryogenic vacuum valve with opening and closing times as short as 50 ms that can be used in strong magnetic fields and across a broad range of duty cycles. It is used to seal a cryogenic Penning trap at liquid-helium temperature for long-term storage of highly charged ions in a vacuum better than 10-15 hPa from a room-temperature ion beamline at vacuum conditions around 10-9 hPa. It will significantly improve any experiment where a volume at the most extreme vacuum conditions must be temporarily connected to a less demanding vacuum during repeated experimental cycles. We describe the design of this valve and show measurements that characterize its main features.
Collapse
Affiliation(s)
- J W Klimes
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Universität Heidelberg, Grabengasse 1, 69117 Heidelberg, Germany
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - Kanika
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Universität Heidelberg, Grabengasse 1, 69117 Heidelberg, Germany
| | - A Krishnan
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Technische Universität Darmstadt, Institut für Angewandte Physik, Schlossgartenstraße 7, 64289 Darmstadt, Germany
| | - B Reich
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Universität Heidelberg, Grabengasse 1, 69117 Heidelberg, Germany
| | - K K Anjum
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Friedrich-Schiller-Universität Jena, Max-Wien-Platz 1, 07743 Jena, Germany
| | - P Baus
- Technische Universität Darmstadt, Institut für Angewandte Physik, Schlossgartenstraße 7, 64289 Darmstadt, Germany
| | - G Birkl
- Technische Universität Darmstadt, Institut für Angewandte Physik, Schlossgartenstraße 7, 64289 Darmstadt, Germany
- Helmholtz Forschungsakademie Hessen für FAIR (HFHF), Campus Darmstadt, Schlossgartenstraße 2, 64289 Darmstadt, Germany
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Universität Heidelberg, Grabengasse 1, 69117 Heidelberg, Germany
| | - W Schott
- TUM School of Natural Sciences, Technische Universität München, James-Franck-Str. 1, 85748 Garching, Germany
| | - M Vogel
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| |
Collapse
|
4
|
Smorra C, Abbass F, Schweitzer D, Bohman M, Devine JD, Dutheil Y, Hobl A, Arndt B, Bauer BB, Devlin JA, Erlewein S, Fleck M, Jäger JI, Latacz BM, Micke P, Schiffelholz M, Umbrazunas G, Wiesinger M, Will C, Wursten E, Yildiz H, Blaum K, Matsuda Y, Mooser A, Ospelkaus C, Quint W, Soter A, Walz J, Yamazaki Y, Ulmer S. BASE-STEP: A transportable antiproton reservoir for fundamental interaction studies. Rev Sci Instrum 2023; 94:113201. [PMID: 37972020 DOI: 10.1063/5.0155492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 10/09/2023] [Indexed: 11/19/2023]
Abstract
Currently, the world's only source of low-energy antiprotons is the AD/ELENA facility located at CERN. To date, all precision measurements on single antiprotons have been conducted at this facility and provide stringent tests of fundamental interactions and their symmetries. However, magnetic field fluctuations from the facility operation limit the precision of upcoming measurements. To overcome this limitation, we have designed the transportable antiproton trap system BASE-STEP to relocate antiprotons to laboratories with a calm magnetic environment. We anticipate that the transportable antiproton trap will facilitate enhanced tests of charge, parity, and time-reversal invariance with antiprotons and provide new experimental possibilities of using transported antiprotons and other accelerator-produced exotic ions. We present here the technical design of the transportable trap system. This includes the transportable superconducting magnet, the cryogenic inlay consisting of the trap stack and detection systems, and the differential pumping section to suppress the residual gas flow into the cryogenic trap chamber.
Collapse
Affiliation(s)
- C Smorra
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
| | - F Abbass
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - D Schweitzer
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - M Bohman
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | | | - A Hobl
- Bilfinger Noell GmbH, Würzburg, Germany
| | - B Arndt
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - B B Bauer
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
| | - J A Devlin
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
- CERN, Geneva, Switzerland
| | - S Erlewein
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- CERN, Geneva, Switzerland
| | - M Fleck
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
| | - J I Jäger
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- CERN, Geneva, Switzerland
| | - B M Latacz
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
- CERN, Geneva, Switzerland
| | - P Micke
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- CERN, Geneva, Switzerland
| | - M Schiffelholz
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover, Germany
| | - G Umbrazunas
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
- Eidgenössisch Technische Hochschule Zürich, Zürich, Switzerland
| | - M Wiesinger
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - C Will
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - E Wursten
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
- CERN, Geneva, Switzerland
| | - H Yildiz
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - Y Matsuda
- Graduate School of Arts and Sciences, University of Tokyo, Tokyo, Japan
| | - A Mooser
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - C Ospelkaus
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover, Germany
- Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - A Soter
- Eidgenössisch Technische Hochschule Zürich, Zürich, Switzerland
| | - J Walz
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - Y Yamazaki
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
| | - S Ulmer
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
- RIKEN, Fundamental Symmetries Laboratory, Wako, Japan
| |
Collapse
|
5
|
Latacz BM, Arndt BP, Devlin JA, Erlewein SR, Fleck M, Jäger JI, Micke P, Umbrazunas G, Wursten E, Abbass F, Schweitzer D, Wiesinger M, Will C, Yildiz H, Blaum K, Matsuda Y, Mooser A, Ospelkaus C, Smorra C, Sótér A, Quint W, Walz J, Yamazaki Y, Ulmer S. Ultra-thin polymer foil cryogenic window for antiproton deceleration and storage. Rev Sci Instrum 2023; 94:103310. [PMID: 37874231 DOI: 10.1063/5.0167262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Accepted: 08/17/2023] [Indexed: 10/25/2023]
Abstract
We present the design and characterization of a cryogenic window based on an ultra-thin aluminized biaxially oriented polyethylene terephthalate foil at T < 10 K, which can withstand a pressure difference larger than 1 bar at a leak rate <1×10-9 mbar l/s. Its thickness of ∼1.7 μm makes it transparent to various types of particles over a broad energy range. To optimize the transfer of 100 keV antiprotons through the window, we tested the degrading properties of different aluminum coated polymer foils of thicknesses between 900 and 2160 nm, concluding that 1760 nm foil decelerates antiprotons to an average energy of 5 keV. We have also explicitly studied the permeation as a function of coating thickness and temperature and have performed extensive thermal and mechanical endurance and stress tests. Our final design integrated into the experiment has an effective open surface consisting of seven holes with a diameter of 1 mm and will transmit up to 2.5% of the injected 100 keV antiproton beam delivered by the Antiproton Decelerator and Extra Low ENergy Antiproton ring facility of CERN.
Collapse
Affiliation(s)
- B M Latacz
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - B P Arndt
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
- GSI-Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, D-64291 Darmstadt, Germany
| | - J A Devlin
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S R Erlewein
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - M Fleck
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Graduate School of Arts and Sciences, University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo 153-0041, Japan
| | - J I Jäger
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - P Micke
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - G Umbrazunas
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Eidgenössische Technische Hochschule Zürich, John-von-Neumann-Weg 9, 8093 Zürich, Switzerland
| | - E Wursten
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - F Abbass
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, D-55099 Mainz, Germany
| | - D Schweitzer
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, D-55099 Mainz, Germany
| | - M Wiesinger
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - C Will
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - H Yildiz
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, D-55099 Mainz, Germany
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - Y Matsuda
- Graduate School of Arts and Sciences, University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo 153-0041, Japan
| | - A Mooser
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - C Ospelkaus
- Institut für Quantenoptik, Leibniz Universität, Welfengarten 1, D-30167 Hannover, Germany
- Physikalisch-Technische Bundesanstalt, Bundesallee 100, D-38116 Braunschweig, Germany
| | - C Smorra
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, D-55099 Mainz, Germany
| | - A Sótér
- Eidgenössische Technische Hochschule Zürich, John-von-Neumann-Weg 9, 8093 Zürich, Switzerland
| | - W Quint
- GSI-Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, D-64291 Darmstadt, Germany
| | - J Walz
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, D-55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität, Staudingerweg 18, D-55128 Mainz, Germany
| | - Y Yamazaki
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Ulmer
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
6
|
Sanchez DF, Fernández-Nestosa MJ, Alemany L, Cañete-Portillo S, Lloveras B, Clavero O, Rodríguez I, Quint W, Muñoz N, de Sanjosé S, Bosch FX, Cubilla AL. Detection of variable genotypes in common human papillomavirus-associated invasive penile squamous cell carcinomas: a study of 177 human papillomavirus-positive cases. Hum Pathol 2023; 139:65-72. [PMID: 37429448 DOI: 10.1016/j.humpath.2023.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 06/29/2023] [Accepted: 07/05/2023] [Indexed: 07/12/2023]
Abstract
Human papillomavirus (HPV) is detected in 30-50% of invasive penile carcinomas, and it is frequently associated with basaloid and warty morphological features. Based on this heterogeneity and different clinical behaviors, we hypothesized a variation in their HPV genotypic composition. To test this, we evaluated 177 HPV-positive cases: basaloid (114), warty-basaloid (28), and warty (condylomatous) (35) invasive carcinomas. HPV DNA detection and genotyping was performed using the SPF-10/DEIA/LiPA25 system. Nineteen HPV genotypes were detected. High-risk HPVs predominated (96%), and low-risk HPVs were rarely present. Most common genotype was HPV16 followed by HPVs 33 and 35. According to the genotypes identified, 93% of the cases would be covered with current vaccination programs. There was a significant variation in the distribution of HPV16 and non-HPV16 genotypes according to histological subtype. HPV16 was significantly frequent in basaloid (87%) and was less frequent in warty carcinomas (61%). This molecular difference, along with their distinctive macro-microscopic and prognostic features, makes basaloid and warty carcinomas unique. The gradual decreasing frequency of HPV16 demonstrated in basaloid, warty-basaloid, and warty carcinomas suggest that the basaloid cell, present in those types in decreasing proportions, may be responsible for the differences.
Collapse
Affiliation(s)
- Diego F Sanchez
- Instituto de Patología e Investigación, Asunción 1228, Paraguay; Translational Oncogenomics Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester Cancer Research Centre, Manchester M20 4GJ, UK
| | | | - Laia Alemany
- Institut Català D'Oncologia, Barcelona 08908, Spain
| | | | | | - Omar Clavero
- Institut Català D'Oncologia, Barcelona 08908, Spain
| | - Ingrid Rodríguez
- Instituto de Patología e Investigación, Asunción 1228, Paraguay; Universidad Nacional de Asunción, San Lorenzo 2111, Paraguay
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk 2288, Netherlands
| | - Nubia Muñoz
- National Cancer Institute of Colombia, Bogotá 111511-110411001, Colombia
| | - Silvia de Sanjosé
- Barcelona Institute for Global Health (ISGlobal), Barcelona 08036, Spain
| | | | - Antonio L Cubilla
- Instituto de Patología e Investigación, Asunción 1228, Paraguay; Universidad Nacional de Asunción, San Lorenzo 2111, Paraguay.
| |
Collapse
|
7
|
Sasidharan S, Bezrodnova O, Rau S, Quint W, Sturm S, Blaum K. Penning-Trap Mass Measurement of Helium-4. Phys Rev Lett 2023; 131:093201. [PMID: 37721828 DOI: 10.1103/physrevlett.131.093201] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 08/04/2023] [Indexed: 09/20/2023]
Abstract
Light-ion trap (LIONTRAP), a high-precision Penning-trap mass spectrometer, was used to determine the atomic mass of ^{4}He. Here, we report a 12 parts-per-trillion measurement of the mass of a ^{4}He^{2+} ion, m(^{4}He^{2+})=4.001 506 179 651(48) u. From this, the atomic mass of the neutral atom can be determined without loss of precision: m(^{4}He)=4.002 603 254 653(48) u. This result is slightly more precise than the current CODATA18 literature value but deviates by 6.6 standard deviations.
Collapse
Affiliation(s)
- S Sasidharan
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
- Heidelberg University, Grabengasse 1, 69117 Heidelberg, Germany
| | - O Bezrodnova
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - S Rau
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - S Sturm
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| |
Collapse
|
8
|
Latacz BM, Arndt BP, Bauer BB, Devlin JA, Erlewein SR, Fleck M, Jäger JI, Schiffelholz M, Umbrazunas G, Wursten EJ, Abbass F, Micke P, Popper D, Wiesinger M, Will C, Yildiz H, Blaum K, Matsuda Y, Mooser A, Ospelkaus C, Quint W, Soter A, Walz J, Yamazaki Y, Smorra C, Ulmer S. BASE-high-precision comparisons of the fundamental properties of protons and antiprotons. Eur Phys J D At Mol Opt Phys 2023; 77:94. [PMID: 37288385 PMCID: PMC10241734 DOI: 10.1140/epjd/s10053-023-00672-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Accepted: 05/01/2023] [Indexed: 06/09/2023]
Abstract
Abstract The BASE collaboration at the antiproton decelerator/ELENA facility of CERN compares the fundamental properties of protons and antiprotons with ultra-high precision. Using advanced Penning trap systems, we have measured the proton and antiproton magnetic moments with fractional uncertainties of 300 parts in a trillion (p.p.t.) and 1.5 parts in a billion (p.p.b.), respectively. The combined measurements improve the resolution of the previous best test in that sector by more than a factor of 3000. Very recently, we have compared the antiproton/proton charge-to-mass ratios with a fractional precision of 16 p.p.t., which improved the previous best measurement by a factor of 4.3. These results allowed us also to perform a differential matter/antimatter clock comparison test to limits better than 3 %. Our measurements enable us to set limits on 22 coefficients of CPT- and Lorentz-violating standard model extensions (SME) and to search for potentially asymmetric interactions between antimatter and dark matter. In this article, we review some of the recent achievements and outline recent progress towards a planned improved measurement of the antiproton magnetic moment with an at least tenfold improved fractional accuracy. Graphic Abstract
Collapse
Affiliation(s)
- B. M. Latacz
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
| | - B. P. Arndt
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- GSI-Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - B. B. Bauer
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, 55099 Mainz, Germany
| | - J. A. Devlin
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
| | - S. R. Erlewein
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - M. Fleck
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- Graduate School of Arts and Sciences, University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo, 153-0041 Japan
| | - J. I. Jäger
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - M. Schiffelholz
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- Institut für Quantenoptik, Leibniz Universität, Welfengarten 1, 30167 Hannover, Germany
| | - G. Umbrazunas
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- Eidgenössisch Technische Hochschule Zürich, Rämistrasse 101, 8092 Zürich, Switzerland
| | - E. J. Wursten
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
| | - F. Abbass
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, 55099 Mainz, Germany
| | - P. Micke
- CERN, Esplanade des Particules 1, 1217 Meyrin, Switzerland
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - D. Popper
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, 55099 Mainz, Germany
| | - M. Wiesinger
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - C. Will
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - H. Yildiz
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, 55099 Mainz, Germany
| | - K. Blaum
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - Y. Matsuda
- Graduate School of Arts and Sciences, University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo, 153-0041 Japan
| | - A. Mooser
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - C. Ospelkaus
- Institut für Quantenoptik, Leibniz Universität, Welfengarten 1, 30167 Hannover, Germany
- Physikalisch-Technische Bundesanstalt, Bundesallee 100, 38116 Braunschweig, Germany
| | - W. Quint
- GSI-Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - A. Soter
- Eidgenössisch Technische Hochschule Zürich, Rämistrasse 101, 8092 Zürich, Switzerland
| | - J. Walz
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, 55099 Mainz, Germany
- Helmholtz-Institut Mainz, Johannes Gutenberg-Universität, Staudingerweg 18, 55128 Mainz, Germany
| | - Y. Yamazaki
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
| | - C. Smorra
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, 55099 Mainz, Germany
| | - S. Ulmer
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
- Heinrich-Heine Universität, Universitätsstraße 1, 40225 Düsseldorf, Germany
| |
Collapse
|
9
|
Ahmed SR, Befano B, Lemay A, Egemen D, Rodriguez AC, Angara S, Desai K, Jeronimo J, Antani S, Campos N, Inturrisi F, Perkins R, Kreimer A, Wentzensen N, Herrero R, Del Pino M, Quint W, de Sanjose S, Schiffman M, Kalpathy-Cramer J. REPRODUCIBLE AND CLINICALLY TRANSLATABLE DEEP NEURAL NETWORKS FOR CANCER SCREENING. Res Sq 2023:rs.3.rs-2526701. [PMID: 36909463 PMCID: PMC10002800 DOI: 10.21203/rs.3.rs-2526701/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Cervical cancer is a leading cause of cancer mortality, with approximately 90% of the 250,000 deaths per year occurring in low- and middle-income countries (LMIC). Secondary prevention with cervical screening involves detecting and treating precursor lesions; however, scaling screening efforts in LMIC has been hampered by infrastructure and cost constraints. Recent work has supported the development of an artificial intelligence (AI) pipeline on digital images of the cervix to achieve an accurate and reliable diagnosis of treatable precancerous lesions. In particular, WHO guidelines emphasize visual triage of women testing positive for human papillomavirus (HPV) as the primary screen, and AI could assist in this triage task. Published AI reports have exhibited overfitting, lack of portability, and unrealistic, near-perfect performance estimates. To surmount recognized issues, we implemented a comprehensive deep-learning model selection and optimization study on a large, collated, multi-institutional dataset of 9,462 women (17,013 images). We evaluated relative portability, repeatability, and classification performance. The top performing model, when combined with HPV type, achieved an area under the Receiver Operating Characteristics (ROC) curve (AUC) of 0.89 within our study population of interest, and a limited total extreme misclassification rate of 3.4%, on held-aside test sets. Our work is among the first efforts at designing a robust, repeatable, accurate and clinically translatable deep-learning model for cervical screening.
Collapse
Affiliation(s)
- Syed Rakin Ahmed
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA
- Harvard Graduate Program in Biophysics, Harvard Medical School, Harvard University, Cambridge, MA 02115, USA
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH 02139,USA
| | - Brian Befano
- Information Management Services, Calverton, MD 20705, USA
- University of Washington, Seattle, WA 98195, USA
| | - Andreanne Lemay
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA
- NeuroPoly, Polytechnique Montreal, Montreal, QC H3T 1N8, Canada
| | - Didem Egemen
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Ana Cecilia Rodriguez
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Sandeep Angara
- Computational Health Research Branch, National Library of Medicine, Lister Hill Center, Bethesda, MD 20894
| | - Kanan Desai
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Jose Jeronimo
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Sameer Antani
- Computational Health Research Branch, National Library of Medicine, Lister Hill Center, Bethesda, MD 20894
| | - Nicole Campos
- Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston MA 02115
| | - Federica Inturrisi
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Rebecca Perkins
- Dept of Obstetrics & Gynecology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118
| | - Aimee Kreimer
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Nicolas Wentzensen
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Rolando Herrero
- Agencia Costarricense de Investigaciones Biomedicas (ACIB), Fundacion INCIENSA, San Jose, Costa Rica
| | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | - Silvia de Sanjose
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
- ISGlobal, Barcelona, Spain
| | - Mark Schiffman
- Clinical Epidemiology Unit, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | - Jayashree Kalpathy-Cramer
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA
| |
Collapse
|
10
|
Hu SY, Kreimer AR, Porras C, Guillén D, Alfaro M, Darragh TM, Stoler MH, Villegas LF, Ocampo R, Rodriguez AC, Schiffman M, Tsang SH, Lowy DR, Schiller JT, Schussler J, Quint W, Gail MH, Sampson JN, Hildesheim A, Herrero R. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial. J Natl Cancer Inst 2022; 114:1253-1261. [PMID: 35640980 PMCID: PMC9468298 DOI: 10.1093/jnci/djac107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 03/26/2022] [Accepted: 05/18/2022] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND We investigated the impact of human papillomavirus (HPV) vaccination on the performance of cytology-based and HPV-based screening for detection of cervical precancer among women vaccinated as young adults and reaching screening age. METHODS A total of 4632 women aged 25-36 years from the Costa Rica HPV Vaccine Trial were included (2418 HPV-vaccinated as young adults and 2214 unvaccinated). We assessed the performance of cytology- and HPV-based cervical screening modalities in vaccinated and unvaccinated women to detect high-grade cervical precancers diagnosed over 4 years and the absolute risk of cumulative cervical precancers by screening results at entry. RESULTS We detected 95 cervical intraepithelial neoplasia grade 3 or worse (52 in unvaccinated and 43 in vaccinated women). HPV16/18/31/33/45 was predominant (69%) among unvaccinated participants, and HPV35/52/58/39/51/56/59/66/68 predominated (65%) among vaccinated participants. Sensitivity and specificity of cervical screening approaches were comparable between women vaccinated as young adults and unvaccinated women. Colposcopy referral rates were lower in the vaccinated group for HPV-based screening modalities, but the positive predictive value was comparable between the 2 groups. CONCLUSIONS Among women approaching screening ages, vaccinated as young adults, and with a history of intensive screening, the expected reduction in the positive predictive value of HPV testing, associated with dropping prevalence of HPV-associated lesions, was not observed. This is likely due to the presence of high-grade lesions associated with nonvaccine HPV types, which may be less likely to progress to cancer.
Collapse
Affiliation(s)
- Shang-Ying Hu
- Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Aimée R Kreimer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Carolina Porras
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), Fundación INCIENSA, San José, Costa Rica
| | - Diego Guillén
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), Fundación INCIENSA, San José, Costa Rica
| | - Mario Alfaro
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), Fundación INCIENSA, San José, Costa Rica
| | - Teresa M Darragh
- School of Medicine, University of California, San Francisco, CA, USA
| | - Mark H Stoler
- Department of Pathology, University of Virginia, Charlottesville, VA, USA
| | - Luis F Villegas
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), Fundación INCIENSA, San José, Costa Rica
| | - Rebecca Ocampo
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), Fundación INCIENSA, San José, Costa Rica
| | | | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Sabrina H Tsang
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Douglas R Lowy
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Rockville, MD, USA
| | - John T Schiller
- Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Rockville, MD, USA
| | | | - Wim Quint
- Viroclinics-DDL, Rijswijk, Netherlands
| | - Mitchell H Gail
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Joshua N Sampson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Allan Hildesheim
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Rolando Herrero
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), Fundación INCIENSA, San José, Costa Rica
- Early Detection Prevention and Infections, International Agency for Research on Cancer, Lyon, France
| | | |
Collapse
|
11
|
Völksen F, Devlin JA, Borchert MJ, Erlewein SR, Fleck M, Jäger JI, Latacz BM, Micke P, Nuschke P, Umbrazunas G, Wursten EJ, Abbass F, Bohman MA, Popper D, Wiesinger M, Will C, Blaum K, Matsuda Y, Mooser A, Ospelkaus C, Smorra C, Soter A, Quint W, Walz J, Yamazaki Y, Ulmer S. A high-Q superconducting toroidal medium frequency detection system with a capacitively adjustable frequency range >180 kHz. Rev Sci Instrum 2022; 93:093303. [PMID: 36182508 DOI: 10.1063/5.0089182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
We describe a newly developed polytetrafluoroethylene/copper capacitor driven by a cryogenic piezoelectric slip-stick stage and demonstrate with the chosen layout cryogenic capacitance tuning of ≈60 pF at ≈10 pF background capacitance. Connected to a highly sensitive superconducting toroidal LC circuit, we demonstrate tuning of the resonant frequency between 345 and 685 kHz, at quality factors Q > 100 000. Connected to a cryogenic ultra low noise amplifier, a frequency tuning range between 520 and 710 kHz is reached, while quality factors Q > 86 000 are achieved. This new device can be used as a versatile image current detector in high-precision Penning-trap experiments or as an LC-circuit-based haloscope detector to search for the conversion of axion-like dark matter to radio-frequency photons. This new development increases the sensitive detection bandwidth of our axion haloscope by a factor of ≈1000.
Collapse
Affiliation(s)
- F Völksen
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J A Devlin
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M J Borchert
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S R Erlewein
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Fleck
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J I Jäger
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - B M Latacz
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - P Micke
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - P Nuschke
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - G Umbrazunas
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - E J Wursten
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - F Abbass
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, D-55099 Mainz, Germany
| | - M A Bohman
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D Popper
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, D-55099 Mainz, Germany
| | - M Wiesinger
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - C Will
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - Y Matsuda
- Graduate School of Arts and Sciences, University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo 153-0041, Japan
| | - A Mooser
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - C Ospelkaus
- Institut für Quantenoptik, Leibniz Universität, Welfengarten 1, D-30167 Hannover, Germany
| | - C Smorra
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Soter
- Eidgenössisch Technische Hochschule Zürich, Rämistrasse 101, 8092 Zürich, Switzerland
| | - W Quint
- GSI-Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, D-64291 Darmstadt, Germany
| | - J Walz
- Institut für Physik, Johannes Gutenberg-Universität, Staudinger Weg 7, D-55099 Mainz, Germany
| | - Y Yamazaki
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Ulmer
- RIKEN, Ulmer Fundamental Symmetries Laboratory, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
12
|
Mena M, Wang X, Tous S, Quiros B, Clavero O, Alejo M, Morey F, Taberna M, Leon Vintro X, Lloveras Rubio B, Alos L, Mehanna H, Quint W, Pawlita M, Tommasino M, Pavón MA, Muñoz N, De Sanjose S, Bosch FX, Alemany L. Concordance of p16 INK4a and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study. Cancers (Basel) 2022; 14:3787. [PMID: 35954451 PMCID: PMC9367257 DOI: 10.3390/cancers14153787] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Revised: 07/26/2022] [Accepted: 07/29/2022] [Indexed: 11/29/2022] Open
Abstract
Background: Tests or test algorithms for diagnosing HPV-driven oral cavity and laryngeal head and neck carcinomas (HNC) have not been yet validated, and the differences among oral cavity and laryngeal sites have not been comprehensively evaluated. We aimed to assess the utility of a diagnostic algorithm for the detection of HPV-driven oral cavity (OCC), oropharyngeal (OPC) and laryngeal (LC) carcinomas using HPV-DNA testing followed by p16INK4a immunohistochemistry, taking E6*I mRNA detection as the reference standard. Methods: Formalin-fixed paraffin-embedded OCC, OPC, and LC carcinomas were collected from pathology archives in 29 countries. All samples were subjected to histopathological evaluation, DNA quality control, and HPV-DNA detection. All HPV-DNA-positive samples (including 78 OCC, 257 OPC, and 51 LC out of 3680 HNC with valid HPV-DNA results) were also tested for p16INK4a immunohistochemistry and E6*I mRNA. Three different cutoffs of nuclear and cytoplasmic staining were evaluated for p16INK4a: (a) >25%, (b) >50%, and (c) ≥70%. The concordance of p16INK4a and E6*I mRNA among HPV-DNA-positive OCC, OPC, and LC cases was assessed. Results: A total of 78 OCC, 257 OPC, and 51 LC were HPV-DNA-positive and further tested for p16INK4a and E6*I mRNA. The percentage of concordance between p16INK4a (cutoff ≥ 70%) and E6*I mRNA among HPV-DNA-positive OCC, OPC, and LC cases was 79.5% (95% CI 69.9−89.1%), 82.1% (95% CI 77.2−87.0%), and 56.9% (95% CI 42.3−71.4%), respectively. A p16INK4a cutoff of >50% improved the concordance although the improvement was not statistically significant. For most anatomical locations and p16INK4a cutoffs, the percentage of discordant cases was higher for HPV16- than HPV-non16-positive cases. Conclusions: The diagnostic algorithm of HPV-DNA testing followed by p16INK4a immunohistochemistry might be helpful in the diagnosis of HPV-driven OCC and OPC, but not LC. A different p16INK4a expression pattern was observed in those cases HPV-DNA-positive for types other than HPV16, as compared to HPV16-positive cases. Our study provides new insights into the use HPV-DNA, p16INK4a, and HPV-E6*I mRNA for diagnosing an HPV-driven HNC, including the optimal HPV test or p16INK4a cutoffs to be used. More studies are warranted to clarify the role of p16INK4a and HPV status in both OPC and non-OPC HNC.
Collapse
Affiliation(s)
- Marisa Mena
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Xin Wang
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
| | - Sara Tous
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Beatriz Quiros
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Omar Clavero
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Maria Alejo
- Pathology Department, Hospital de Vic, 08500 Vic, Spain
- Pathology Department, Hospital General de l’Hopitalet, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
| | - Francisca Morey
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
| | - Miren Taberna
- Oncology Department, Catalan Institute of Oncology (ICO)-IDIBELL, ONCOBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
| | - Xavier Leon Vintro
- Otorhinolaryngology Department, Hospital Sant Pau, 08026 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | | | - Llúcia Alos
- Pathology Department, Hospital Clinic, 08036 Barcelona, Spain
| | - Hisham Mehanna
- Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham B15 2TT, UK
| | - Wim Quint
- DDL Diagnostic Laboratory, 2288 ER Rijswijk, The Netherlands
| | - Michael Pawlita
- Division of Molecular Diagnostics of Oncogenic Infections, Research Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Massimo Tommasino
- Infections and Cancer Biology Group, International Agency for Research on Cancer (IARC), 69372 Lyon, France
| | - Miguel Angel Pavón
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Nubia Muñoz
- National Cancer Institute, Bogotá 111511, Colombia
| | - Silvia De Sanjose
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
- ISGlobal, 08036 Barcelona, Spain
| | - Francesc Xavier Bosch
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
- Universitat Oberta de Catalunya, 08035 Barcelona, Spain
| | - Laia Alemany
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | | |
Collapse
|
13
|
Sierra MS, Tsang SH, Porras C, Herrero R, Sampson JN, Cortes B, Schussler J, Wagner S, Carvajal L, Quint W, Kreimer AR, Hu S, Rodriguez AC, Romero B, Hildesheim A. Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial. Sex Transm Infect 2022; 99:sextrans-2022-055434. [PMID: 35842229 PMCID: PMC10176398 DOI: 10.1136/sextrans-2022-055434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 05/28/2022] [Indexed: 11/04/2022] Open
Abstract
INTRODUCTION Human papillomavirus (HPV) vaccines protect against incident HPV infections, which cause cervical cancer. OBJECTIVES We estimated the prevalence and incidence of HPV infections in young adult women to understand the impact of an HPV vaccination programme in this population. METHODS We collected cervical specimens from 6322 unvaccinated women, aged 18-37 years, who participated in the Costa Rica Vaccine Trial and its long-term follow-up. Women were followed for (median) 4.8 years and had (median) 4.0 study visits. Cervical specimens were tested for the presence/absence of 25 HPV genotypes. For each age band, we estimated the percentage of women with 1+ prevalent or 1+ incident HPV infections using generalised estimating equations. We also estimated the prevalence and incidence of HPV as a function of time since first sexual intercourse (FSI). RESULTS The model estimated HPV incident infections peaked at 28.0% (95% CI 25.3% to 30.9%) at age 20 years then steadily declined to 11.8% (95% CI 7.6% to 17.8%) at age 37 years. Incident oncogenic HPV infections (HPV16/18/31/33/35/39/45/51/52/56/58/59) peaked and then declined from 20.3% (95% CI 17.9% to 22.9%) to 7.7% (95% CI 4.4% to 13.1%); HPV16/18 declined from 6.4% (95% CI 5.1% to 8.1%) to 1.1% (95% CI 0.33% to 3.6%) and HPV31/33/45/52/58 declined from 11.0% (95% CI 9.3% to 13.1%) to 4.5% (95% CI 2.2% to 8.9%) over the same ages. The percentage of women with 1+ incident HPV of any, oncogenic, non-oncogenic and vaccine-preventable (HPV16/18, HPV31/33/45, HPV31/33/45/52/58, and HPV6/11) types peaked <1 year after FSI and steadily declined with increasing time since FSI (p for trends <0.001). We observed similar patterns for model estimated HPV prevalences. CONCLUSION Young adult women may benefit from HPV vaccination if newly acquired vaccine-preventable oncogenic infections lead to cervical precancer and cancer. HPV vaccination targeting this population may provide additional opportunities for primary prevention. TRIAL REGISTRATION NUMBER NCT00128661.
Collapse
Affiliation(s)
- Mónica S Sierra
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
| | - Sabrina H Tsang
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
| | - Carolina Porras
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San Jose, Costa Rica
| | - Rolando Herrero
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San Jose, Costa Rica
- Early Detection and Prevention Section, International Agency for Research on Cancer, Lyon, Rhône-Alpes, France
| | - Joshua N Sampson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
| | - Bernal Cortes
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San Jose, Costa Rica
| | - John Schussler
- Information Management Services Inc, Silver Spring, Maryland, USA
| | - Sarah Wagner
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Frederick, Maryland, USA
| | - Loretto Carvajal
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San Jose, Costa Rica
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | - Aimée R Kreimer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
| | - Shangying Hu
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
- Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | | - Byron Romero
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San Jose, Costa Rica
| | - Allan Hildesheim
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
| |
Collapse
|
14
|
Pedersen H, Ejegod DM, Quint W, Xu L, Arbyn M, Bonde J. Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework. J Mol Diagn 2022; 24:365-373. [PMID: 35123039 DOI: 10.1016/j.jmoldx.2021.12.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 11/08/2021] [Accepted: 12/15/2021] [Indexed: 10/19/2022] Open
Abstract
The clinical performance evaluation of the novel MassARRAY human papillomavirus (MA-HPV) assay was performed using Danish SurePath cervical cancer screening samples under the fourth Validation of HPV Genotyping Tests (VALGENT) framework. The MA-HPV assay is a mass array-based assay that individually detects 14 oncogenic HPV genotypes and five nononcogenic types. The MA-HPV assay was validated using the VALGENT4 panel, which constitutes 997 consecutive samples from a screening population in addition to 297 disease-enriched samples with abnormal cytology findings. The clinical accuracy of the MA-HPV assay for sensitivity and specificity was assessed relative to that of the general primer 5+/6+ PCR enzyme immunoassay (GP-EIA), by a noninferiority test. The type-specific concordance of the MA-HPV assay was assessed as well. The relative sensitivity of the MA-HPV assay for cervical intraepithelial neoplasia ≥2 or ≥3 was 1.02 (95% CI, 0.98-1.05) and 1.01 (95% CI, 0.99-1.04), respectively. The sensitivity of the MA-HPV was noninferior to that of the GP-EIA (P = 0.0001), whereas the specificity of the MA-HPV was inferior (0.89; 95% CI, 0.85-0.91; P > 0.99). The MA-HPV assay is a clinical sensitive assay with a lower clinical specificity compared with the GP-EIA. The assay in its current form seems more suited to play a role where specificity is of lesser importance but where high sensitivity is paramount.
Collapse
Affiliation(s)
- Helle Pedersen
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Hvidovre, Denmark
| | - Ditte M Ejegod
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Hvidovre, Denmark
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, the Netherlands
| | - Lan Xu
- Belgian Cancer Centre/Unit of Cancer Epidemiology, Brussels, Belgium
| | - Marc Arbyn
- Belgian Cancer Centre/Unit of Cancer Epidemiology, Brussels, Belgium
| | - Jesper Bonde
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Hvidovre, Denmark.
| |
Collapse
|
15
|
Shabaev VM, Glazov DA, Ryzhkov AM, Brandau C, Plunien G, Quint W, Volchkova AM, Zinenko DV. Ground-State g Factor of Highly Charged ^{229}Th Ions: An Access to the M1 Transition Probability between the Isomeric and Ground Nuclear States. Phys Rev Lett 2022; 128:043001. [PMID: 35148134 DOI: 10.1103/physrevlett.128.043001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Accepted: 12/21/2021] [Indexed: 06/14/2023]
Abstract
A method is proposed to determine the M1 nuclear transition amplitude and hence the lifetime of the "nuclear clock transition" between the low-lying (∼8 eV) first isomeric state and the ground state of ^{229}Th from a measurement of the ground-state g factor of few-electron ^{229}Th ions. As a tool, the effect of nuclear hyperfine mixing in highly charged ^{229}Th ions such as ^{229}Th^{89+} or ^{229}Th^{87+} is used. The ground-state-only g-factor measurement would also provide first experimental evidence of nuclear hyperfine mixing in atomic ions. Combining the measurements for H-, Li-, and B-like ^{229}Th ions has a potential to improve the initial result for a single charge state and to determine the nuclear magnetic moment to a higher accuracy than that of the currently accepted value. The calculations include relativistic, interelectronic-interaction, QED, and nuclear effects.
Collapse
Affiliation(s)
- V M Shabaev
- Department of Physics, St. Petersburg State University, Universitetskaya 7/9, 199034 St. Petersburg, Russia
| | - D A Glazov
- Department of Physics, St. Petersburg State University, Universitetskaya 7/9, 199034 St. Petersburg, Russia
| | - A M Ryzhkov
- Department of Physics, St. Petersburg State University, Universitetskaya 7/9, 199034 St. Petersburg, Russia
| | - C Brandau
- I. Physikalisches Institut, Justus-Liebig-Universität, Heinrich-Buff-Ring 16, D-35392 Giessen, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, D-64291 Darmstadt, Germany
| | - G Plunien
- Institut für Theoretische Physik, TU Dresden, Mommsenstrasse 13, Dresden, D-01062, Germany
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, D-64291 Darmstadt, Germany
| | - A M Volchkova
- Department of Physics, St. Petersburg State University, Universitetskaya 7/9, 199034 St. Petersburg, Russia
| | - D V Zinenko
- Department of Physics, St. Petersburg State University, Universitetskaya 7/9, 199034 St. Petersburg, Russia
| |
Collapse
|
16
|
Borchert MJ, Devlin JA, Erlewein SR, Fleck M, Harrington JA, Higuchi T, Latacz BM, Voelksen F, Wursten EJ, Abbass F, Bohman MA, Mooser AH, Popper D, Wiesinger M, Will C, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Yamazaki Y, Smorra C, Ulmer S. A 16-parts-per-trillion measurement of the antiproton-to-proton charge-mass ratio. Nature 2022; 601:53-57. [PMID: 34987217 DOI: 10.1038/s41586-021-04203-w] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 11/03/2021] [Indexed: 11/09/2022]
Abstract
The standard model of particle physics is both incredibly successful and glaringly incomplete. Among the questions left open is the striking imbalance of matter and antimatter in the observable universe1, which inspires experiments to compare the fundamental properties of matter/antimatter conjugates with high precision2-5. Our experiments deal with direct investigations of the fundamental properties of protons and antiprotons, performing spectroscopy in advanced cryogenic Penning trap systems6. For instance, we previously compared the proton/antiproton magnetic moments with 1.5 parts per billion fractional precision7,8, which improved upon previous best measurements9 by a factor of greater than 3,000. Here we report on a new comparison of the proton/antiproton charge-to-mass ratios with a fractional uncertainty of 16 parts per trillion. Our result is based on the combination of four independent long-term studies, recorded in a total time span of 1.5 years. We use different measurement methods and experimental set-ups incorporating different systematic effects. The final result, [Formula: see text], is consistent with the fundamental charge-parity-time reversal invariance, and improves the precision of our previous best measurement6 by a factor of 4.3. The measurement tests the standard model at an energy scale of 1.96 × 10-27 gigaelectronvolts (confidence level 0.68), and improves ten coefficients of the standard model extension10. Our cyclotron clock study also constrains hypothetical interactions mediating violations of the clock weak equivalence principle (WEPcc) for antimatter to less than 1.8 × 10-7, and enables the first differential test of the WEPcc using antiprotons11. From this interpretation we constrain the differential WEPcc-violating coefficient to less than 0.030.
Collapse
Affiliation(s)
- M J Borchert
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,Institut für Quantenoptik, Leibniz Universität Hannover, Hannover, Germany.,Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
| | - J A Devlin
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,CERN, Meyrin, Switzerland
| | - S R Erlewein
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,CERN, Meyrin, Switzerland.,Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M Fleck
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,Graduate School of Arts and Sciences, University of Tokyo, Tokyo, Japan
| | - J A Harrington
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - T Higuchi
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,Graduate School of Arts and Sciences, University of Tokyo, Tokyo, Japan
| | - B M Latacz
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan
| | - F Voelksen
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,GSI-Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - E J Wursten
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,CERN, Meyrin, Switzerland.,Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - F Abbass
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - M A Bohman
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A H Mooser
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - D Popper
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - M Wiesinger
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - C Will
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - Y Matsuda
- Graduate School of Arts and Sciences, University of Tokyo, Tokyo, Japan
| | - C Ospelkaus
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover, Germany.,Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
| | - W Quint
- GSI-Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - J Walz
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany.,Helmholtz-Institut Mainz, Johannes Gutenberg-Universität, Mainz, Germany
| | - Y Yamazaki
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan
| | - C Smorra
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.,Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - S Ulmer
- Ulmer Fundamental Symmetries Laboratory, RIKEN, Saitama, Japan.
| |
Collapse
|
17
|
Sierra MS, Tsang SH, Hu S, Porras C, Herrero R, Kreimer AR, Schussler J, Boland J, Wagner S, Cortes B, Rodríguez AC, Quint W, van Doorn LJ, Schiffman M, Sampson JN, Hildesheim A. Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. J Infect Dis 2021; 224:503-516. [PMID: 33326576 PMCID: PMC8496490 DOI: 10.1093/infdis/jiaa768] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Accepted: 12/11/2020] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Factors that lead human papillomavirus (HPV) infections to persist and progress to cancer are not fully understood. We evaluated co-factors for acquisition, persistence, and progression of non-HPV-16/18 infections among HPV-vaccinated women. METHODS We analyzed 2153 women aged 18-25 years randomized to the HPV-vaccine arm of the Costa Rica HPV Vaccine Trial. Women were HPV DNA negative for all types at baseline and followed for approximately 11 years. Generalized estimating equation methods were used to account for correlated observations. Time-dependent factors evaluated were age, sexual behavior, marital status, hormonally related factors, number of full-term pregnancies (FTPs), smoking behavior, and baseline body mass index. RESULTS A total of 1777 incident oncogenic non-HPV-16/18 infections were detected in 12 292 visits (average, 0.14 infections/visit). Age and sexual behavior-related variables were associated with oncogenic non-HPV-16/18 acquisition. Twenty-six percent of incident infections persisted for ≥1 year. None of the factors evaluated were statistically associated with persistence of oncogenic non-HPV-16/18 infections. Risk of progression to Cervical Intraepithelial Neoplasia grade 2 or worst (CIN2+) increased with increasing age (P for trend = .001), injectable contraceptive use (relative risk, 2.61 [95% confidence interval, 1.19-5.73] ever vs never), and increasing FTPs (P for trend = .034). CONCLUSIONS In a cohort of HPV-16/18-vaccinated women, age and sexual behavior variables are associated with acquisition of oncogenic non-HPV-16/18 infections; no notable factors are associated with persistence of acquired infections; and age, parity, and hormonally related exposures are associated with progression to CIN2+.
Collapse
Affiliation(s)
- Mónica S Sierra
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
| | - Sabrina H Tsang
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
| | - Shangying Hu
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
| | - Carolina Porras
- Agencia Costarricense de Investigaciones Biomédicas,
formerly Proyecto Epidemiológico Guanacaste, Fundación
INCIENSA, San José, Costa
Rica
| | - Rolando Herrero
- Agencia Costarricense de Investigaciones Biomédicas,
formerly Proyecto Epidemiológico Guanacaste, Fundación
INCIENSA, San José, Costa
Rica
- Prevention and Implementation Group, International Agency
for Research on Cancer, Lyon, France
| | - Aimée R Kreimer
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
| | - John Schussler
- Information Management Services, Silver
Spring, Maryland, USA
| | - Joseph Boland
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
- Cancer Genomics Research Laboratory, Frederick National
Laboratory for Cancer Research, Leidos Biomedical Research Inc,
Frederick, Maryland, USA
| | - Sarah Wagner
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
- Cancer Genomics Research Laboratory, Frederick National
Laboratory for Cancer Research, Leidos Biomedical Research Inc,
Frederick, Maryland, USA
| | - Bernal Cortes
- Agencia Costarricense de Investigaciones Biomédicas,
formerly Proyecto Epidemiológico Guanacaste, Fundación
INCIENSA, San José, Costa
Rica
| | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk,
The Netherlands
| | | | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
| | - Joshua N Sampson
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
| | - Allan Hildesheim
- Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA
| |
Collapse
|
18
|
Bohman M, Grunhofer V, Smorra C, Wiesinger M, Will C, Borchert MJ, Devlin JA, Erlewein S, Fleck M, Gavranovic S, Harrington J, Latacz B, Mooser A, Popper D, Wursten E, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Ulmer S. Sympathetic cooling of a trapped proton mediated by an LC circuit. Nature 2021; 596:514-518. [PMID: 34433946 PMCID: PMC8387233 DOI: 10.1038/s41586-021-03784-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Accepted: 06/29/2021] [Indexed: 02/07/2023]
Abstract
Efficient cooling of trapped charged particles is essential to many fundamental physics experiments1,2, to high-precision metrology3,4 and to quantum technology5,6. Until now, sympathetic cooling has required close-range Coulomb interactions7,8, but there has been a sustained desire to bring laser-cooling techniques to particles in macroscopically separated traps5,9,10, extending quantum control techniques to previously inaccessible particles such as highly charged ions, molecular ions and antimatter. Here we demonstrate sympathetic cooling of a single proton using laser-cooled Be+ ions in spatially separated Penning traps. The traps are connected by a superconducting LC circuit that enables energy exchange over a distance of 9 cm. We also demonstrate the cooling of a resonant mode of a macroscopic LC circuit with laser-cooled ions and sympathetic cooling of an individually trapped proton, reaching temperatures far below the environmental temperature. Notably, as this technique uses only image-current interactions, it can be easily applied to an experiment with antiprotons1, facilitating improved precision in matter-antimatter comparisons11 and dark matter searches12,13.
Collapse
Affiliation(s)
- M Bohman
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany.
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan.
| | - V Grunhofer
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - C Smorra
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - M Wiesinger
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
| | - C Will
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M J Borchert
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover, Germany
- Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
| | - J A Devlin
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
- CERN, Geneva, Switzerland
| | - S Erlewein
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
- CERN, Geneva, Switzerland
| | - M Fleck
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
- Graduate School of Arts and Sciences, University of Tokyo, Tokyo, Japan
| | - S Gavranovic
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - J Harrington
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
| | - B Latacz
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
| | - A Mooser
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - D Popper
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
| | - E Wursten
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
- CERN, Geneva, Switzerland
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - Y Matsuda
- Graduate School of Arts and Sciences, University of Tokyo, Tokyo, Japan
| | - C Ospelkaus
- Institut für Quantenoptik, Leibniz Universität Hannover, Hannover, Germany
- Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - J Walz
- Institut für Physik, Johannes Gutenberg-Universität, Mainz, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - S Ulmer
- RIKEN, Fundamental Symmetries Laboratory, Saitama, Japan
| |
Collapse
|
19
|
Tota JE, Struyf F, Hildesheim A, Gonzalez P, Ryser M, Herrero R, Schussler J, Karkada N, Rodriguez AC, Folschweiller N, Porras C, Schiffman M, Schiller JT, Quint W, Kreimer AR, Lehtinen M, Wheeler CM, Sampson JN. Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. J Infect Dis 2021; 223:1576-1581. [PMID: 32887990 PMCID: PMC8248553 DOI: 10.1093/infdis/jiaa561] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Accepted: 09/01/2020] [Indexed: 11/13/2022] Open
Abstract
Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.
Collapse
Affiliation(s)
- Joseph E Tota
- Divison of Cancer Epidemiology and Genetics, National
Cancer Institute, Rockville, Maryland, USA
| | | | - Allan Hildesheim
- Divison of Cancer Epidemiology and Genetics, National
Cancer Institute, Rockville, Maryland, USA
| | - Paula Gonzalez
- Agencia Costarricense de Investigaciones Biomédicas,
Fundación INCIENSA, Guanacaste, Costa
Rica
| | | | - Rolando Herrero
- Agencia Costarricense de Investigaciones Biomédicas,
Fundación INCIENSA, Guanacaste, Costa
Rica
- Section of Early Detection and Prevention, International
Agency for Research on Cancer, Lyon, France
| | - John Schussler
- Information Management Services, Rockville,
Maryland, USA
| | | | | | | | - Carolina Porras
- Proyecto Epidemiológico Guanacaste, Fundación
INCIENSA, San José, Costa
Rica
| | - Mark Schiffman
- Divison of Cancer Epidemiology and Genetics, National
Cancer Institute, Rockville, Maryland, USA
| | - John T Schiller
- Center for Cancer Research, National Cancer
Institute, Bethesda, Maryland, USA
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk,
the Netherlands
| | - Aimée R Kreimer
- Divison of Cancer Epidemiology and Genetics, National
Cancer Institute, Rockville, Maryland, USA
| | - Matti Lehtinen
- University of Tampere, School of Public
Health, Tampere, Finland
| | - Cosette M Wheeler
- Department of Pathology and Obstetrics and Gynecology,
University of New Mexico Cancer Center, Albuquerque, New Mexico,
USA
| | - Joshua N Sampson
- Divison of Cancer Epidemiology and Genetics, National
Cancer Institute, Rockville, Maryland, USA
| |
Collapse
|
20
|
Bhatia R, Boada EA, Bonde J, Quint W, Christiansen IK, Xu L, Ejegod DM, Moncur S, Cuschieri K, Arbyn M. Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework. J Virol Methods 2021; 294:114161. [PMID: 33895238 DOI: 10.1016/j.jviromet.2021.114161] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 01/29/2021] [Accepted: 04/09/2021] [Indexed: 11/29/2022]
Abstract
AIM The VALidation of HPV GENotyping Tests (VALGENT) is a framework for comparison and validation of HPV tests with genotyping capabilities. In this study, the clinical performance of a single tube HPV test -HarmoniaHPV- was assessed in SurePath™ samples and compared to a clinically validated reference test, the GP5+/6+ Enzyme ImmunoAssay (GP5+/6 + EIA). METHODS HarmoniaHPV test is a real-time, PCR based, limited genotyping HPV test which detects 14 high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 with HPV16, and HPV 18 reported individually. Clinical performance was assessed using 998 unselected, cervical screening samples enriched with 297 cytologically abnormal specimens (100 atypical squamous cells of unspecified significance, 100 low-grade squamous intraepithelial lesions, 97 high-grade squamous intraepithelial lesions). Cases were defined as women diagnosed with histologically confirmed cervical intraepithelial neoplasia 2 or more (≥CIN2, N = 122). RESULTS Using the manufacturer recommended (un-adjusted) cut-offs, HarmoniaHPV had non-inferior sensitivity for detection of ≥ CIN2 but showed inferior specificity. A cut-off optimisation exercise was therefore carried out and optimised cut-offs for each individual channel rendered a sensitivity and specificity of HarmoniaHPV that was non-inferior to GP5+/6 + EIA. Analytically, the test showed excellent intra- and inter-laboratory reproducibility, which improved further with the use of the optimised cut-offs. CONCLUSION HarmoniaHPV when operated with optimised cut-offs fulfils the international clinical criteria for use in cervical cancer screening on SurePath samples. The optimised cut-offs warrant additional testing and independent validation.
Collapse
Affiliation(s)
- Ramya Bhatia
- HPV Research Group, University of Edinburgh, EH16 4TJ, Edinburgh, Scotland, United Kingdom; Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, EH16 4SA, Edinburgh, Scotland, United Kingdom.
| | - Elia Alcañiz Boada
- HPV Research Group, University of Edinburgh, EH16 4TJ, Edinburgh, Scotland, United Kingdom
| | - Jesper Bonde
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Kettegårds Alle 30, 2650, Hvidovre, Denmark
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, the Netherlands
| | - Irene Kraus Christiansen
- Norwegian HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, 1478, Lørenskog, Norway
| | - Lan Xu
- Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Juliette Wytsmanstreet 14, B1050, Brussels, Belgium
| | - Ditte Møller Ejegod
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Kettegårds Alle 30, 2650, Hvidovre, Denmark
| | - Sharon Moncur
- Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, EH16 4SA, Edinburgh, Scotland, United Kingdom
| | - Kate Cuschieri
- Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, EH16 4SA, Edinburgh, Scotland, United Kingdom
| | - Marc Arbyn
- Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Juliette Wytsmanstreet 14, B1050, Brussels, Belgium; Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium
| |
Collapse
|
21
|
Shim TN, Harwood CA, Marsh SG, Gotch FM, Quint W, de Koning MN, Francis N, Jameson C, Freeman A, Minhas S, Muneer A, Dinneen M, Bunker CB. The prevalence of human leucocyte antigen and human papillomavirus DNA in penile intraepithelial neoplasia in England 2011-2012. Int J STD AIDS 2021; 32:388-395. [PMID: 33576716 DOI: 10.1177/0956462420970727] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The pathogenesis of penile intraepithelial neoplasia (PeIN) is unclear but human papillomavirus (HPV) infection and polymorphisms in human leucocyte antigen (HLA). OBJECTIVES To examine the prevalence of HPV DNA and HLA in PeIN. METHODS Adult Caucasian men with a clinical and histological diagnosis of PeIN, that is, Bowenoid papulosis (BP), Bowen's disease of penis (BDP) and erythroplasia of Queyrat (EQ) were selected and phenotyped from the clinical records. DNA was extracted from blood and paraffin-embedded sections for HLA and HPV typing, respectively. Human leucocyte antigen allele frequencies were compared with those derived from the UK-based Caucasian population. RESULTS Seventy-two cases of PeIN (20 BP, 34 BDP and 18 EQ) were studied. Human papillomavirus DNA was identified in 65/72 (90.2%) PeIN; Alphapapillomavirus types were detected in 62/72 (85%) followed by Betapapillomavirus types in 9/72 (12.5%) and cutaneous types in 7/72 (9.7%); HPV16 was the most prevalent genotype at 35/72 (48.6%) followed by HPV33 at 7/72 (9.7%); multiple infections were seen in 18/72 (25%) PeIN. HLA-C*15 (Bonferroni corrected p = 0.049) confers susceptibility to PeIN, whereas HLA-DQA1*01 (corrected p = 0.02) protects against PeIN. HPV16-associated PeIN cases showed no statistically significant association with HLA genotype after multiple corrections. CONCLUSION Human papillomavirus is involved in the pathogenesis of PeIN. Immunogenotype may play a role in the pathogenesis of PeIN.
Collapse
Affiliation(s)
- Tang Ngee Shim
- Dermatology Department, University College Hospital, Chelsea and Westminster Hospital, London, UK
| | - Catherine A Harwood
- Center for Cutaneous Research and Cell Biology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Steven Ge Marsh
- Anthony Nolan Research Institute and University College London Cancer Institute, London, UK
| | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, Netherlands
| | | | - Nick Francis
- Pathology Department, Imperial College Healthcare NHS Trust, London, UK
| | - Charles Jameson
- Pathology Department, 4919University College London Hospital, London, UK
| | - Alex Freeman
- Pathology Department, 4919University College London Hospital, London, UK
| | - Suks Minhas
- Andrology Centre and the Institute of Urology, 4919University College London Hospital, London, UK
| | - Asif Muneer
- Andrology Centre and the Institute of Urology, 4919University College London Hospital, London, UK
| | - Michael Dinneen
- Urology Department, Chelsea and Westminster Hospital, London, UK
| | - Christopher B Bunker
- Dermatology Department, University College Hospital, Chelsea and Westminster Hospital, London, UK
| |
Collapse
|
22
|
Stratton P, Battiwalla M, Tian X, Abdelazim S, Baird K, Barrett AJ, Cantilena CR, Childs RW, DeJesus J, Fitzhugh C, Fowler D, Gea-Banacloche J, Gress RE, Hickstein D, Hsieh M, Ito S, Kemp TJ, Khachikyan I, Merideth MA, Pavletic SZ, Quint W, Schiffman M, Scrivani C, Shanis D, Shenoy AG, Struijk L, Tisdale JF, Wagner S, Williams KM, Yu Q, Wood LV, Pinto LA. Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial. JAMA Oncol 2021; 6:696-705. [PMID: 32105293 DOI: 10.1001/jamaoncol.2019.6722] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Importance Human papillomavirus (HPV) infection is found in about 40% of women who survive allogeneic hematopoietic stem cell transplant and can induce subsequent neoplasms. Objective To determine the safety and immunogenicity of the quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) in clinically stable women post-allogeneic transplant compared with female healthy volunteers. Interventions Participants received the quadrivalent HPV vaccine in intramuscular injections on days 1 and 2 and then 6 months later. Design, Setting, and Participants This prospective, open-label phase-1 study was conducted in a government clinical research hospital and included clinically stable women posttransplant who were or were not receiving immunosuppressive therapy compared with healthy female volunteers age 18 to 50 years who were followed up or a year after first receiving quadrivalent HPV vaccination. The study was conducted from June 2, 2010, until July 19, 2016. After all of the results of the study assays were completed and available in early 2018, the analysis took place from February 2018 to May 2019. Main Outcomes and Measures Anti-HPV-6, -11, -16, and -18-specific antibody responses using L1 virus-like particle enzyme-linked immunosorbent assay were measured in serum before (day 1) and at months 7 and 12 postvaccination. Anti-HPV-16 and -18 neutralization titers were determined using a pseudovirion-based neutralization assay. Results Of 64 vaccinated women, 23 (35.9%) were receiving immunosuppressive therapy (median age, 34 years [range, 18-48 years]; median 1.2 years posttransplant), 21 (32.8%) were not receiving immunosuppression (median age, 32 years [range, 18-49 years]; median 2.5 years posttransplant), and 20 (31.3%) were healthy volunteers (median age, 32 years [range, 23-45 years]). After vaccine series completion, 18 of 23 patients receiving immunosuppression (78.3%), 20 of 21 not receiving immunosuppression (95.2%), and all 20 volunteers developed antibody responses to all quadrivalent HPV vaccine types (P = .04, comparing the 3 groups). Geometric mean antibody levels for each HPV type were higher at months 7 and 12 than at baseline in each group (all geometric mean ratios >1; P < .001) but not significantly different across groups. Antibody and neutralization titers for anti-HPV-16 and anti-HPV-18 correlated at month 7 (Spearman ρ = 0.92; P < .001 for both). Adverse events were mild and not different across groups. Conclusions and Relevance Treatment with the HPV vaccination was followed by strong, functionally active antibody responses against vaccine-related HPV types and no serious adverse events. These findings suggest that HPV vaccination may be safely administered to women posttransplant to potentially reduce HPV infection and related neoplasia. Trial Registration ClinicalTrials.gov Identifier: NCT01092195.
Collapse
Affiliation(s)
- Pamela Stratton
- Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.,Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
| | - Minoo Battiwalla
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.,Sarah Cannon Research Institute, Nashville, Tennessee
| | - Xin Tian
- Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Suzanne Abdelazim
- Clinical Center, National Institutes of Health, Bethesda, Maryland.,Riverside Regional Medical Center, Newport News, Virginia
| | - Kristin Baird
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - A John Barrett
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.,GW Cancer Center, The George Washington University Hospital, Washington, DC
| | - Caroline R Cantilena
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.,University of Kansas School of Medicine, Kansas City
| | - Richard W Childs
- Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Jessica DeJesus
- Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Courtney Fitzhugh
- Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Daniel Fowler
- Experimental Transplant and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.,Rapa Therapeutics, Rockville, Maryland
| | - Juan Gea-Banacloche
- Experimental Transplant and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.,Infectious Diseases Division, Mayo Clinic Arizona, Phoenix, Arizona
| | - Ronald E Gress
- Experimental Transplant and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Dennis Hickstein
- Experimental Transplant and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Matthew Hsieh
- Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Sawa Ito
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.,Hematopoietic Stem Cell Transplant and Cell Therapy, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Troy J Kemp
- HPV Immunology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | - Izabella Khachikyan
- Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.,Office of New Drugs, Center for Drug Evaluation and Research, Division of Anesthesia, Analgesia, and Addiction Products, US Food and Drug Administration, Silver Spring, Maryland
| | - Melissa A Merideth
- Office of the Clinical Director, National Human Genome Research Institute, Bethesda, Maryland
| | - Steven Z Pavletic
- Experimental Transplant and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, the Netherlands
| | - Mark Schiffman
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland
| | - Claire Scrivani
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.,University of Virginia School of Medicine, Charlottesville
| | - Dana Shanis
- Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.,Rittenhouse Women's Wellness Center, Philadelphia, Pennsylvania
| | - Aarthi G Shenoy
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.,Department of Hematology/Oncology, MedStar Washington Hospital Center, Washington, DC
| | - Linda Struijk
- DDL Diagnostic Laboratory, Rijswijk, the Netherlands
| | - John F Tisdale
- Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Sarah Wagner
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Frederick, Maryland
| | - Kirsten M Williams
- Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.,Children's Research Institute, Children's National, Washington, DC
| | - Quan Yu
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Lauren V Wood
- Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.,PDS Biotechnology, Berkeley Heights, New Jersey
| | - Ligia A Pinto
- HPV Immunology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| |
Collapse
|
23
|
Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, Schiller JT, Schiffman M, Schussler J, Gail MH, Quint W, Ocampo R, Morales J, Rodríguez AC, Hu S, Sampson JN, Kreimer AR. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol 2020; 21:1643-1652. [PMID: 33271093 PMCID: PMC8724969 DOI: 10.1016/s1470-2045(20)30524-6] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 08/17/2020] [Accepted: 08/20/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Oncogenic human papillomavirus (HPV) infections cause most cases of cervical cancer. Here, we report long-term follow-up results for the Costa Rica Vaccine Trial (publicly funded and initiated before licensure of the HPV vaccines), with the aim of assessing the efficacy of the bivalent HPV vaccine for preventing HPV 16/18-associated cervical intraepithelial neoplasia grade 2 or worse (CIN2+). METHODS Women aged 18-25 years were enrolled in a randomised, double-blind, controlled trial in Costa Rica, between June 28, 2004, and Dec 21, 2005, designed to assess the efficacy of a bivalent vaccine for the prevention of infection with HPV 16/18 and associated precancerous lesions at the cervix. Participants were randomly assigned (1:1) to receive an HPV 16/18 AS04-adjuvanted vaccine or control hepatitis A vaccine. Vaccines were administered intramuscularly in three 0·5 mL doses at 0, 1, and 6 months and participants were followed up annually for 4 years. After the blinded phase, women in the HPV vaccine group were invited to enrol in the long-term follow-up study, which extended follow-up for 7 additional years. The control group received HPV vaccine and was replaced with a new unvaccinated control group. Women were followed up every 2 years until year 11. Investigators and patients were aware of treatment allocation for the follow-up phase. At each visit, clinicians collected cervical cells from sexually active women for cytology and HPV testing. Women with abnormal cytology were referred to colposcopy, biopsy, and treatment as needed. Women with negative results at the last screening visit (year 11) exited the long-term follow-up study. The analytical cohort for vaccine efficacy included women who were HPV 16/18 DNA-negative at vaccination. The primary outcome of this analysis was defined as histopathologically confirmed CIN2+ or cervical intraepithelial neoplasia grade 3 or worse associated with HPV 16/18 cervical infection detected at colposcopy referral. We calculated vaccine efficacy by year and cumulatively. This long-term follow-up study is registered with ClinicalTrials.gov, NCT00867464. FINDINGS 7466 women were enrolled in the Costa Rica Vaccine Trial; 3727 received the HPV vaccine and 3739 received the control vaccine. Between March 30, 2009, and July 5, 2012, 2635 women in the HPV vaccine group and 2836 women in the new unvaccinated control group were enrolled in the long-term follow-up study. 2635 women in the HPV vaccine group and 2677 women in the control group were included in the analysis cohort for years 0-4, and 2073 women from the HPV vaccine group and 2530 women from the new unvaccinated control group were included in the analysis cohort for years 7-11. Median follow-up time for the HPV group was 11·1 years (IQR 9·1-11·7), 4·6 years (4·3-5·3) for the original control group, and 6·2 years (5·5-6·9) for the new unvaccinated control group. At year 11, vaccine efficacy against incident HPV 16/18-associated CIN2+ was 100% (95% CI 89·2-100·0); 34 (1·5%) of 2233 unvaccinated women had a CIN2+ outcome compared with none of 1913 women in the HPV group. Cumulative vaccine efficacy against HPV 16/18-associated CIN2+ over the 11-year period was 97·4% (95% CI 88·0-99·6). Similar protection was observed against HPV 16/18-associated CIN3-specifically at year 11, vaccine efficacy was 100% (95% CI 78·8-100·0) and cumulative vaccine efficacy was 94·9% (73·7-99·4). During the long-term follow-up, no serious adverse events occurred that were deemed related to the HPV vaccine. The most common grade 3 or worse serious adverse events were pregnancy, puerperium, and perinatal conditions (in 255 [10%] of 2530 women in the unvaccinated control group and 201 [10%] of 2073 women in the HPV vaccine group). Four women in the unvaccinated control group and three in the HPV vaccine group died; no deaths were deemed to be related to the HPV vaccine. INTERPRETATION The bivalent HPV vaccine has high efficacy against HPV 16/18-associated precancer for more than a decade after initial vaccination, supporting the notion that invasive cervical cancer is preventable. FUNDING US National Cancer Institute.
Collapse
Affiliation(s)
- Carolina Porras
- Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, San José, Costa Rica.
| | - Sabrina H Tsang
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Rolando Herrero
- Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, San José, Costa Rica; Early Detection and Prevention Section, International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Diego Guillén
- Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, San José, Costa Rica
| | | | - Mark H Stoler
- Department of Pathology, University of Virginia, Charlottesville, VA, USA
| | - Allan Hildesheim
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Sarah Wagner
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA
| | - Joseph Boland
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA
| | - Douglas R Lowy
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - John T Schiller
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | | | - Mitchell H Gail
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, Netherlands
| | - Rebeca Ocampo
- Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, San José, Costa Rica
| | - Jorge Morales
- Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, San José, Costa Rica
| | | | - Shangying Hu
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Joshua N Sampson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Aimée R Kreimer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| |
Collapse
|
24
|
Rakislova N, Alemany L, Clavero O, Saco A, Torné A, del Pino M, Munmany M, Rodrigo-Calvo MT, Guerrero J, Marimon L, Vega N, Quirós B, Lloveras B, Ribera-Cortada I, Alejo M, Pawlita M, Quint W, de Sanjose S, Ordi J. p53 Immunohistochemical Patterns in HPV-Independent Squamous Cell Carcinomas of the Vulva and the Associated Skin Lesions: A Study of 779 Cases. Int J Mol Sci 2020; 21:ijms21218091. [PMID: 33138328 PMCID: PMC7662853 DOI: 10.3390/ijms21218091] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Revised: 10/27/2020] [Accepted: 10/28/2020] [Indexed: 12/12/2022] Open
Abstract
Human papillomavirus (HPV)-independent vulvar squamous cell carcinomas (VSCC) and its precursors frequently harbour TP53 mutations. Recently, six p53 immunohistochemical (IHC) patterns have been defined, which have shown strong correlation with TP53 mutation status. However, few studies have applied this new six-pattern framework and none of them exhaustively compared p53 IHC positivity and patterns between invasive VSCC and adjacent skin lesion. We performed p53 IHC in a series of 779 HPV-independent VSCC with adjacent skin and evaluated the IHC slides following the newly described classification. Some 74.1% invasive VSCC showed abnormal p53 IHC staining. A skin lesion was identified in 450 cases (57.8%), including 254 intraepithelial precursors and 196 inflammatory/reactive lesions. Two hundred and ten of 450 (47%) VSCC with associated skin lesions showed an abnormal p53 IHC stain, with an identical staining pattern between the VSCC and the adjacent skin lesion in 80% of the cases. A total of 144/450 (32%) VSCC showed wild-type p53 IHC both in the invasive VSCC and adjacent skin lesion. Finally, 96/450 (21%) VSCC showed p53 IHC abnormal staining in the invasive VSCC but a wild-type p53 staining in the skin lesion. Most of the discordant cases (70/96; 73%) showed adjacent inflammatory lesions. In conclusion, the p53 IHC staining and pattern are usually identical in the VSCC and the intraepithelial precursor.
Collapse
Affiliation(s)
- Natalia Rakislova
- Department of Pathology, ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain; (N.R.); (A.S.); (M.T.R.-C.); (J.G.); (L.M.); (N.V.); (I.R.-C.)
| | - Laia Alemany
- Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, 08908 L’Hospitalet de Llobregat, Spain; (L.A.); (O.C.); (B.Q.)
- CIBER Epidemiologia y Salud Pública, 28029 Madrid, Spain
| | - Omar Clavero
- Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, 08908 L’Hospitalet de Llobregat, Spain; (L.A.); (O.C.); (B.Q.)
- CIBER Epidemiologia y Salud Pública, 28029 Madrid, Spain
| | - Adela Saco
- Department of Pathology, ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain; (N.R.); (A.S.); (M.T.R.-C.); (J.G.); (L.M.); (N.V.); (I.R.-C.)
| | - Aureli Torné
- Institute of Gynecology, Obstetrics and Neonatology, Hospital Clínic—Institut d´Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Faculty of Medicine-University of Barcelona, 08036 Barcelona, Spain; (A.T.); (M.d.P.); (M.M.)
| | - Marta del Pino
- Institute of Gynecology, Obstetrics and Neonatology, Hospital Clínic—Institut d´Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Faculty of Medicine-University of Barcelona, 08036 Barcelona, Spain; (A.T.); (M.d.P.); (M.M.)
| | - Meritxell Munmany
- Institute of Gynecology, Obstetrics and Neonatology, Hospital Clínic—Institut d´Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Faculty of Medicine-University of Barcelona, 08036 Barcelona, Spain; (A.T.); (M.d.P.); (M.M.)
| | - Maria Teresa Rodrigo-Calvo
- Department of Pathology, ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain; (N.R.); (A.S.); (M.T.R.-C.); (J.G.); (L.M.); (N.V.); (I.R.-C.)
| | - José Guerrero
- Department of Pathology, ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain; (N.R.); (A.S.); (M.T.R.-C.); (J.G.); (L.M.); (N.V.); (I.R.-C.)
| | - Lorena Marimon
- Department of Pathology, ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain; (N.R.); (A.S.); (M.T.R.-C.); (J.G.); (L.M.); (N.V.); (I.R.-C.)
| | - Naiara Vega
- Department of Pathology, ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain; (N.R.); (A.S.); (M.T.R.-C.); (J.G.); (L.M.); (N.V.); (I.R.-C.)
| | - Beatriz Quirós
- Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, 08908 L’Hospitalet de Llobregat, Spain; (L.A.); (O.C.); (B.Q.)
| | - Belen Lloveras
- Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain;
| | - Inmaculada Ribera-Cortada
- Department of Pathology, ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain; (N.R.); (A.S.); (M.T.R.-C.); (J.G.); (L.M.); (N.V.); (I.R.-C.)
| | - Maria Alejo
- Department of Pathology, Hospital General d’Hospitalet, 08906 L’Hospitalet de Llobregat, Spain;
| | - Michael Pawlita
- Division of Molecular Diagnostics of Oncogenic Infections, Research Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany;
| | - Wim Quint
- DDL Diagnostic Laboratory, 2288 Rijswijk, The Netherlands;
| | | | - Jaume Ordi
- Department of Pathology, ISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain; (N.R.); (A.S.); (M.T.R.-C.); (J.G.); (L.M.); (N.V.); (I.R.-C.)
- CIBER Epidemiologia y Salud Pública, 28029 Madrid, Spain
- Correspondence: ; Tel.: +34-93-227-5450
| | | |
Collapse
|
25
|
Shim TN, Harwood CA, Marsh SG, Gotch FM, Quint W, de Koning MN, Francis N, Jameson C, Freeman A, Minhas S, Dinneen M, Muneer A, Bunker CB. Immunogenetics and human papillomavirus (HPV) in male genital lichen sclerosus (MGLSc). Int J STD AIDS 2020; 31:1334-1339. [PMID: 33081649 DOI: 10.1177/0956462420949395] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BackgroundThe pathogenesis of male genital lichen sclerosus (MGLSc) is controversial. Incriminated factors include infection with human papillomavirus (HPV) and autoimmunity (e.g. Human Leukocyte Antigen [HLA]). To address the roles of HLA and HPV in MGLSc we studied adult Caucasian males with a clinical and histological diagnosis of MGLSc. The men in the study attended two specialised Male Genital Dermatoses Clinics between July 2011 and September 2012 and were selected and phenotyped from the clinical records. DNA was extracted from blood and paraffin-embedded biopsy sections, for HLA and HPV typing, respectively. HLA allele frequencies were compared with those derived from the UK-based Caucasian population. Eighty-eight cases of MGLSc were identified. HPV DNA was detected in 33/88 (37.5%) cases of MGLSc. HPV16 was the most prevalent type found: 11/88 (12.5%) MGLSc. No statistically significant HLA associations were established but HLA-B*35, -B*51, -C*15, -DRB1*04, -DRB1*10 (predisposition) and -DQA1*01 (protection) were revealed as alleles of interest. HPV16-associated MGLSc cases showed no statistically significant association with HLA genotype. The relationship between HPV and MGLSc suggests a passenger effect rather than a pathogenic role. HLA is not associated with MGLSc nor co-existent HPV16.
Collapse
Affiliation(s)
- Tang Ngee Shim
- Dermatology Department, University College Hospital, Chelsea and Westminster Hospital, London, UK
| | - Catherine A Harwood
- Center for Cutaneous Research and Cell Biology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Steven Ge Marsh
- Anthony Nolan Research Institute, University College London Cancer Institute, London, UK
| | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, the Netherlands
| | | | - Nick Francis
- Pathology Department, Imperial College Healthcare NHS Trust, London, UK
| | - Charles Jameson
- Pathology Department, University College London Hospital, London, UK
| | - Alex Freeman
- Pathology Department, University College London Hospital, London, UK
| | - Suks Minhas
- Andrology Centre and the Institute of Urology, University College London Hospital, London, UK
| | - Michael Dinneen
- Urology Department, Chelsea and Westminster Hospital, London, UK
| | - Asif Muneer
- Andrology Centre and the Institute of Urology, University College London Hospital, London, UK
| | - Christopher B Bunker
- Dermatology Department, University College Hospital, Chelsea and Westminster Hospital, London, UK
| |
Collapse
|
26
|
Tsang SH, Sampson JN, Schussler J, Porras C, Wagner S, Boland J, Cortes B, Lowy DR, Schiller JT, Schiffman M, Kemp TJ, Rodriguez AC, Quint W, Gail MH, Pinto LA, Gonzalez P, Hildesheim A, Kreimer AR, Herrero R. Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst 2020; 112:1030-1037. [PMID: 32091596 PMCID: PMC7566371 DOI: 10.1093/jnci/djaa010] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 12/19/2019] [Accepted: 01/14/2020] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND The Costa Rica HPV Vaccine Trial has documented cross-protection of the bivalent HPV vaccine against HPV31/33/45 up to 7 years after vaccination, even with one dose of the vaccine. However, the durability of such protection remains unknown. Here, we evaluate the efficacy of different schedules of the vaccine against HPV31/33/45 out to 11 years postvaccination, expanding to other nontargeted HPV types. METHODS We compared the rates of HPV infection in vaccinated women with the rates in a comparable cohort of unvaccinated women. We estimated the average vaccine efficacy (VEavg) against incident infections and tested for a change in VE over time. RESULTS Among 3-dose women, we observed statistically significant cross-protection against HPV31/33/45 (VEavg = 64.4%, 95% confidence interval [CI] = 57.7% to 70.0%). Additionally, we observed borderline, statistically significant cross-protection against HPV35 (VEavg = 23.2%, 95% CI = 0.3% to 40.8%) and HPV58 (VEavg = 21.2%, 95% CI = 4.2% to 35.3%). There was no decrease in VE over time (two-sided Ptrend > .05 for HPV31, -33, -35, -45, and -58). As a benchmark, VEavg against HPV16/18 was 82.0% (95% CI = 77.3% to 85.7%). Among 1-dose women, we observed comparable efficacy against HPV31/33/45 (VEavg = 54.4%, 95% CI = 21.0% to 73.7%). Acquisition of nonprotected HPV types was similar between vaccinated and unvaccinated women, indicating that the difference in HPV infection rates was not attributable to differential genital HPV exposure. CONCLUSIONS Substantial cross-protection afforded by the bivalent vaccine against HPV31/33/45, and to a lesser extent, HPV35 and HPV58, was sustained and remained stable after 11 years postvaccination, reinforcing the notion that the bivalent vaccine is an effective option for protection against HPV-associated cancers.
Collapse
Affiliation(s)
- Sabrina H Tsang
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Joshua N Sampson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | | | - Carolina Porras
- Agencia Costarricense de Investigaciones Biomédicas, formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica
| | - Sarah Wagner
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Frederick, MD, USA
| | - Joseph Boland
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Frederick, MD, USA
| | - Bernal Cortes
- Agencia Costarricense de Investigaciones Biomédicas, formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica
| | - Douglas R Lowy
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - John T Schiller
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Troy J Kemp
- HPV Immunology Laboratory, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | - Mitchell H Gail
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ligia A Pinto
- HPV Immunology Laboratory, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Paula Gonzalez
- Agencia Costarricense de Investigaciones Biomédicas, formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica
| | - Allan Hildesheim
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Aimée R Kreimer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Rolando Herrero
- Agencia Costarricense de Investigaciones Biomédicas, formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica
- Early Detection and Prevention Section, International Agency for Research on Cancer, Lyon, France
| | | |
Collapse
|
27
|
Tota JE, Struyf F, Sampson JN, Gonzalez P, Ryser M, Herrero R, Schussler J, Karkada N, Rodriguez AC, Folschweiller N, Porras C, Schiffman M, Schiller JT, Quint W, Kreimer AR, Wheeler CM, Hildesheim A. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. J Natl Cancer Inst 2020; 112:818-828. [PMID: 31697384 PMCID: PMC7825474 DOI: 10.1093/jnci/djz222] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 10/23/2019] [Accepted: 04/11/2019] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The AS04-adjuvanted HPV16/18 (AS04-HPV16/18) vaccine provides excellent protection against targeted human papillomavirus (HPV) types and a variable degree of cross-protection against others, including types 6/11/31/33/45. High efficacy against any cervical intraepithelial neoplasia grade 3 or greater (CIN3+; >90%) suggests that lower levels of protection may exist for a wide range of oncogenic HPV types, which is difficult to quantify in individual trials. Pooling individual-level data from two randomized controlled trials, we aimed to evaluate AS04-HPV16/18 vaccine efficacy against incident HPV infections and cervical abnormalities . METHODS Data were available from the Costa Rica Vaccine Trial (NCT00128661) and Papilloma Trial Against Cancer in Young Adults trial (NCT00122681), two large-scale, double-blind randomized controlled trials of the AS04-HPV16/18 vaccine. Primary analyses focused on disease-free women with no detectable cervicovaginal HPV at baseline. RESULTS A total of 12 550 women were included in our primary analyses (HPV arm = 6271, control arm = 6279). Incidence of 6-month persistent oncogenic and nononcogenic infections, excluding known and accepted protected types 6/11/16/18/31/33/45 (focusing on 34/35/39/40/42/43/44/51/52/53/54/56/58/59/66/68/73/70/74), was statistically significantly lower in the HPV arm than in the control arm (efficacy = 9.9%, 95% confidence interval [CI] = 1.7% to 17.4%). Statistically significant efficacy (P < .05) was observed for individual oncogenic types 16/18/31/33/45/52 and nononcogenic types 6/11/53/74. Efficacy against cervical abnormalities (all types) increased with severity, ranging from 27.7% (95% CI = 21.7% to 33.3%) to 58.7% (95% CI = 34.1% to 74.7%) for cytologic outcomes (low-grade squamous intraepithelial neoplasia lesion or greater, and high-grade squamous intraepithelial neoplasia lesion or greater, respectively) and 66.0% (95% CI = 54.4% to 74.9%) to 87.8% (95% CI = 71.1% to 95.7%) for histologic outcomes (CIN2+ and CIN3+, respectively). Comparing Costa Rica Vaccine Trial and Papilloma Trial Against Cancer in Young Adults results, there was no evidence of heterogeneity, except for type 51 (efficacy = -28.6% and 20.7%, respectively; two-sided P = .03). CONCLUSIONS The AS04-HPV16/18 vaccine provides some additional cross-protection beyond established protected types, which partially explains the high efficacy against CIN3+.
Collapse
Affiliation(s)
- Joseph E Tota
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | | | - Joshua N Sampson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Paula Gonzalez
- GSK, Wavre, Belgium
- Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
| | | | - Rolando Herrero
- Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
- Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France
| | | | | | | | | | - Carolina Porras
- Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica
| | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - John T Schiller
- Center for Cancer Research, National Cancer Institute, Bethesda
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, the Netherlands
| | - Aimée R Kreimer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Cosette M Wheeler
- Department of Pathology and Obstetrics and Gynecology, University of New Mexico Cancer Center, Albuquerque, NM
| | - Allan Hildesheim
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | | |
Collapse
|
28
|
Dekker H, Bun RJ, Mulder DC, Breeuwsma N, van der Rhee JI, Guimerà N, Quint W, Vermeer MH, Bouwes Bavinck JN. Human papillomavirus 16-positive supraclavicular cutaneous squamous cell carcinoma metastatic to the level IV supraclavicular lymph nodes. JAAD Case Rep 2020; 6:822-825. [PMID: 32875029 PMCID: PMC7452168 DOI: 10.1016/j.jdcr.2020.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Affiliation(s)
- Hannah Dekker
- Department of Oral and Maxillofacial Surgery, Noord-West Ziekenhuisgroep, Alkmaar, Netherlands
| | - Rolf J Bun
- Department of Oral and Maxillofacial Surgery, Noord-West Ziekenhuisgroep, Alkmaar, Netherlands
| | - Doriene C Mulder
- Department of Oral and Maxillofacial Surgery, Noord-West Ziekenhuisgroep, Alkmaar, Netherlands
| | - Nelly Breeuwsma
- Department of Pathology, Noord-West Ziekenhuisgroep, Alkmaar, Netherlands
| | | | - Núria Guimerà
- DDL Diagnostic Laboratory, Research and Development, Rijswijk, Netherlands
| | - Wim Quint
- DDL Diagnostic Laboratory, Research and Development, Rijswijk, Netherlands
| | - Maarten H Vermeer
- Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands
| | - Jan N Bouwes Bavinck
- Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands
| |
Collapse
|
29
|
Jenkins D, Molijn A, Kazem S, Pirog EC, Alemany L, de Sanjosé S, Dinjens W, Quint W. Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. Int J Cancer 2020; 147:2526-2536. [PMID: 32474915 DOI: 10.1002/ijc.33124] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 02/17/2020] [Accepted: 02/26/2020] [Indexed: 01/06/2023]
Abstract
International surveys find HPV-negativity in up to 30% of cervical adenocarcinomas. We investigated the pathological diagnosis by expert consensus with immunohistochemistry and the presence of somatic mutations in recognised tumour genes in HPV-positive and negative cervical adenocarcinomas (CADC). A sample was selected of 45 paraffin-embedded cervical blocks diagnosed locally as usual cervical adenocarcinoma from a global study. These represented different diagnoses made at previous diagnostic review and HPV status. All were suitable for analysis for somatic tumour associated gene mutations. Three pathologists examined H/E slides and immunohistochemistry for p16, progesterone receptor and p53 and classified the cases. L1 genes from high-risk HPVs and low-risk HPVs were analysed by SPF10 PCR-DEIA-LiPA25 version 1 in whole tissue sections and microdissected tumour and retested by PCR for E6/E7 genes of hrHPVs if negative. Cases were analysed for microsatellite instability and next-generation sequencing mutation analysis. From the 45 cases, 20 cases of usual CADC were confirmed of which 17 (85%) were HPV-positive in tumour cells. The other 25 cases were reclassified as endometrial, serous, clear-cell and gastric-type adenocarcinomas and all were HPV-negative in tumour cells. Careful retesting for HPV DNA and IHC leads to more accurate identification of HPV-positive usual cervical adenocarcinomas. Endometrioid endometrial adenocarcinomas, other uterine adenocarcinoma with multiple somatic mutations were important in misclassification of HPV-negative cases locally managed as cervical adenocarcinoma, as was gastric-type adenocarcinoma with germline STK11 mutation in East Asia. Few consensuses confirmed HPV-negative usual cervical adenocarcinomas showed somatic tumorigenic mutations also seen in some HPV-positive usual CADC.
Collapse
Affiliation(s)
- David Jenkins
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | - Anco Molijn
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | | | | | - Laia Alemany
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d'Oncologia, Barcelona, Spain
| | - Silvia de Sanjosé
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d'Oncologia, Barcelona, Spain
| | - Winand Dinjens
- Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| |
Collapse
|
30
|
Marra E, Siegenbeek van Heukelom ML, Leeman A, Waterboer T, Meijer CJLM, Snijders PJF, King AJ, Cairo I, van Eeden A, Brokking W, van der Weele P, Quint W, Prins JM, de Vries HJC, Schim van der Loeff MF. Virological and Serological Predictors of Anal High-grade Squamous Intraepithelial Lesions Among Human Immunodeficiency Virus-positive Men Who Have Sex With Men. Clin Infect Dis 2020; 68:1377-1387. [PMID: 30165551 DOI: 10.1093/cid/ciy719] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 08/27/2018] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Our objective was to identify virological and serological predictors of anal high-grade squamous intraepithelial lesions (HSIL) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM). METHODS HIV-positive MSM were recruited from a longitudinal study during which anal self-swabs and serum were collected at up to 5 bi-annual visits. Swabs were human papillomavirus (HPV) genotyped, and the type-specific HPV viral load in the anal swabs was determined. Serum antibodies to the E6, E7, E1, E2, and L1 proteins of 7 high-risk HPV (hrHPV) types and HPV6 and 11 were analyzed. The participants who had a high-resolution anoscopy after the last study visit were included in the current analysis. Anal HSIL was diagnosed by histopathological examinations of anal biopsies. The causative HPV type of anal HSIL was determined in whole tissue sections (WTS) and by laser capture micro-dissection if more than one HPV-type was found in WTS. Multivariable logistic regression was used to study whether persistent anal HPV infections, HPV viral loads, and seropositivity for HPV were predictors of anal HSIL, either in general or caused by the concordant HPV type. RESULTS Of 193 HIV-positive MSM, 50 (26%) were diagnosed with anal HSIL. HrHPV persistence in anal swabs was common, varying by hrHPV type between 3-21%. Anal HPV persistence was the only determinant independently associated with anal HSIL, both in general and by concordant, causative HPV type. CONCLUSIONS Persistent HPV infections were strongly associated with anal HSIL, in general as well as for the concordant HPV type.
Collapse
Affiliation(s)
- Elske Marra
- Department of Infectious Diseases, Public Health Service Amsterdam
| | | | | | - Tim Waterboer
- Infections and Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
| | - Chris J L M Meijer
- Department of Pathology, Vrije Universiteit-University Medical Center, Amsterdam
| | - Peter J F Snijders
- Department of Pathology, Vrije Universiteit-University Medical Center, Amsterdam
| | - Audrey J King
- Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven
| | - Irina Cairo
- Department of Dermatology, Onze Lieve Vrouwe Gasthuis (OLVG)
| | - Arne van Eeden
- Department of Internal Medicine, Diagnostisch Centrum (DC) Klinieken
| | - Wilma Brokking
- Department of Internal Medicine, Diagnostisch Centrum (DC) Klinieken
| | - Pascal van der Weele
- Department of Pathology, Vrije Universiteit-University Medical Center, Amsterdam.,Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, the Netherlands
| | - Jan M Prins
- Department of Internal Medicine, Academic Medical Center, University of Amsterdam
| | - Henry J C de Vries
- Department of Infectious Diseases, Public Health Service Amsterdam.,Department of Dermatology, University of Amsterdam.,Amsterdam Infection and Immunity Institute, Academic Medical Center, University of Amsterdam, the Netherlands
| | - Maarten F Schim van der Loeff
- Department of Infectious Diseases, Public Health Service Amsterdam.,Amsterdam Infection and Immunity Institute, Academic Medical Center, University of Amsterdam, the Netherlands
| |
Collapse
|
31
|
Ejegod DM, Hansen M, Christiansen IK, Pedersen H, Quint W, Xu L, Arbyn M, Bonde J. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework. J Clin Virol 2020; 128:104336. [PMID: 32446166 DOI: 10.1016/j.jcv.2020.104336] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 03/05/2020] [Accepted: 03/23/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND The VALidation of HPV Genotyping Tests (VALGENT) framework is an international cooperation designed for comparison and clinical validation of HPV assays with genotyping capabilities. OBJECTIVES Here we addressed the accuracy of the Roche cobas 4800 HPV test using SurePath samples from the Danish cervical cancer screening program under the VALGENT framework. MATERIAL AND METHODS The VALGENT4 panel comprises 998 consecutive SurePath cervical samples from routine screening and 297 SurePath samples enriched for disease (100 ASC-US, 100 LSIL, 97 HSIL). The cobas HPV test is a real-time PCR assay which detects HPV16 and 18 individually and 12 other high-risk (hr) HPV genotypes in one bulk. RESULTS The clinical performance of the cobas test was assessed relative to that of the comparator assay GP5+/6 + PCR Enzyme ImmunoAssay (GP-EIA) by a non-inferiority test. The relative sensitivity for ≥ CIN2 was 1.00 (95% CI: 0.97-1.04) and relative specificity for the control group was 1.02 (95% CI: 1.01-1.04). The cobas test was found non-inferior to that of GP-EIA for both sensitivity and specificity (p-0.0006 and p < 0.0001, respectively). The type specific performance of the cobas test was evaluated using the GP5+/6 + PCR with Luminex genotyping (GP-LMNX) as comparator. The cobas test showed excellent to good concordance (Kappa: 0.70 to 0.90) with GP-LMNX for all three genotype groups in the overall VALGENT population but good to moderate concordance in the Screening population (kappa from 0.56 to 0.80). CONCLUSIONS The cobas HPV test demonstrated non-inferiority to the comparator assay on cervical SurePath screening samples using the VALGENT4 panel.
Collapse
Affiliation(s)
- Ditte Møller Ejegod
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Hvidovre, Kettegård Alle 30, 2650 Hvidovre, Denmark.
| | - Mona Hansen
- National HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, 1478 Lørenskog, Norway
| | - Irene Kraus Christiansen
- National HPV Reference Laboratory, Department of Microbiology and Infection Control, Akershus University Hospital, 1478 Lørenskog, Norway
| | - Helle Pedersen
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Hvidovre, Kettegård Alle 30, 2650 Hvidovre, Denmark
| | - Wim Quint
- DDL diagnostics Laboratory, Rijswijk, Nederlands
| | - Lan Xu
- Unit Cancer Epidemiology, Belgian Cancer Centre, Juliette Wytsmanstreet 14, 1050 Brussels, Belgium
| | - Marc Arbyn
- Unit Cancer Epidemiology, Belgian Cancer Centre, Juliette Wytsmanstreet 14, 1050 Brussels, Belgium
| | - Jesper Bonde
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Hvidovre, Kettegård Alle 30, 2650 Hvidovre, Denmark
| |
Collapse
|
32
|
Venetianer R, Clarke MA, van der Marel J, Tota J, Schiffman M, Dunn ST, Walker J, Zuna R, Quint W, Wentzensen N. Identification of HPV genotypes causing cervical precancer using tissue-based genotyping. Int J Cancer 2020; 146:2836-2844. [PMID: 32037535 DOI: 10.1002/ijc.32919] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2019] [Revised: 01/03/2020] [Accepted: 01/20/2020] [Indexed: 12/12/2022]
Abstract
Identification of high-risk human papillomavirus genotypes causing cervical precancer is crucial for informing HPV vaccine development and efficacy studies, and for determining which types to include in next-generation genotyping assays. Co-occurrence of hrHPV infections is common and complicates carcinogenicity assessment; accurate attribution requires tissue-based genotyping of precancers. We included all women with cervical intraepithelial neoplasia Grade 2 or worse (CIN2+) from the Biopsy Study, an observational study of 690 women enrolled between 2009 and 2012 at the University of Oklahoma. Tissue-based genotyping, including whole tissue sections (WTS) and laser-capture microdissection (LCM), was performed on all precancers with multiple hrHPV infections detected in cytology, totaling over 1,800 HPV genotyping assays. Genotype attribution was compared to hierarchical and proportional hrHPV-type attribution models. Of 276 women with CIN2+, 122 (44.2%) had multiple hrHPV genotypes in cytology. Of 114 women with genotyping data, 94 had one or more hrHPV detected in tissue. Seventy-one women (75.5%) had a single causal hrHPV genotype, while 23 women had multiple hrHPV genotypes causing CIN2+. Ten women had multiple causal infections in a single biopsy, contrary to the previous notion that each lesion is caused by a single type only. While HPV16 was the predominant causal hrHPV genotype using all approaches, the hierarchical model overattributed HPV16, whereas other causal hrHPV genotypes, particularly HPV18 and HPV35, were underattributed. Understanding true causal genotypes is important for the evaluation of vaccine efficacy, to estimate the extent of unmasking, and for type-specific risk assessment in screening and management.
Collapse
Affiliation(s)
- Rebecca Venetianer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD
| | - Megan A Clarke
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD
| | | | - Joseph Tota
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD
| | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD
| | | | - Joan Walker
- University of Oklahoma Health Sciences Center, Oklahoma City, OK
| | - Rosemary Zuna
- University of Oklahoma Health Sciences Center, Oklahoma City, OK
| | - Wim Quint
- Obstetrics and Gynaecology, DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD
| |
Collapse
|
33
|
Griffin H, Mudhar HS, Rundle P, Shiraz A, Mahmood R, Egawa N, Quint W, Rennie IG, Doorbar J. Human papillomavirus type 16 causes a defined subset of conjunctival in situ squamous cell carcinomas. Mod Pathol 2020; 33:74-90. [PMID: 31485010 PMCID: PMC6930848 DOI: 10.1038/s41379-019-0350-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 07/16/2019] [Accepted: 07/16/2019] [Indexed: 11/08/2022]
Abstract
Squamous cell carcinoma of the conjunctiva is associated with a number of risk factors, including HIV infection, iatrogenic immunosuppression and atopy. In addition, several studies have suggested an involvement of HPV, based on the presence of viral DNA, but did not establish whether there was active infection or evidence of causal disease association. In this manuscript, 31 cases of conjunctival in situ squamous cell carcinoma were classified as HPV DNA-positive or -negative, before being analysed by immunohistochemistry to establish the distribution of viral and cellular biomarkers of HPV gene expression. Our panel included p16INK4a, TP53 and MCM, but also the virally encoded E4 gene product, which is abundantly expressed during productive infection. Subsequent in situ detection of HPV mRNA using an RNAscope approach confirmed that early HPV gene expression was occurring in the majority of cases of HPV DNA-positive conjunctival in situ squamous cell carcinoma, with all of these cases occurring in the atopic group. Viral gene expression correlated with TP53 loss, p16INK4a elevation, and extensive MCM expression, in line with our general understanding of E6 and E7's role during transforming infection at other epithelial sites. A characteristic E4 expression pattern was detected in only one case. HPV mRNA was not detected in lower grades of dysplasia, and was not observed in cases that were HPV DNA-negative. Our study demonstrates an active involvement of HPV in the development of a subset of conjunctival in situ squamous cell carcinoma. No high-risk HPV types were detected other than HPV16. It appears that the conjunctiva is a vulnerable epithelial site for HPV-associated transformation. These cancers are defined by their pattern of viral gene expression, and by the distribution of surrogate markers of HPV infection.
Collapse
Affiliation(s)
- Heather Griffin
- Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK
| | - Hardeep Singh Mudhar
- National Specialist Ophthalmic Pathology Service, Department of Histopathology, E-Floor, Royal Hallamshire Hospital, Glossop Rd, Sheffield, S10 2JF, UK
| | - Paul Rundle
- Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Glossop Rd, Sheffield, S10 2JF, UK
| | - Aslam Shiraz
- Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK
| | - Radma Mahmood
- Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill Hill, London, NW7 1AA, UK
| | - Nagayasu Egawa
- Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK
| | - Wim Quint
- Delft Diagnostic Laboratories, Visseringlaan 25, 2288 ER, Rijswijk, The Netherlands
| | - Ian G Rennie
- Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Glossop Rd, Sheffield, S10 2JF, UK
| | - John Doorbar
- Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK.
| |
Collapse
|
34
|
Fernández-Nestosa MJ, Guimerà N, Sanchez DF, Cañete-Portillo S, Lobatti A, Velazquez EF, Jenkins D, Quint W, Cubilla AL. Comparison of Human Papillomavirus Genotypes in Penile Intraepithelial Neoplasia and Associated Lesions: LCM-PCR Study of 87 Lesions in 8 Patients. Int J Surg Pathol 2019; 28:265-272. [PMID: 31735112 DOI: 10.1177/1066896919887802] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Penile intraepithelial neoplasia (PeIN) is currently classified in human papillomavirus (HPV)- and non-HPV-related subtypes with variable HPV genotypes. PeINs are frequently associated with other intraepithelial lesions in the same specimen. The aim of this study was to detect and compare HPV genotypes in PeINs and associated lesions using high-precision laser capture microdissection-polymerase chain reaction and p16INK4a immunostaining. We evaluated resected penile specimens from 8 patients and identified 33 PeINs and 54 associated lesions. The most common subtype was warty PeIN, followed by warty-basaloid and basaloid PeIN. Associated lesions were classical condylomas (17 cases), atypical classical condylomas (2 cases), flat condylomas (9 cases), atypical flat condylomas (6 cases), flat lesions with mild atypia (12 cases), and squamous hyperplasia (8 cases). After a comparison, identical HPV genotypes were found in PeIN and associated lesions in the majority of the patients (7 of 8 patients). HPV16 was the most common genotype present in both PeIN and corresponding associated lesion (50% of the patients). Nonspecific flat lesions with mild atypia, classical condylomas, and atypical condylomas were the type of associated lesions most commonly related to HPV16. Other high-risk HPV genotypes present in PeIN and associated nonspecific flat lesion with mild atypia were HPV35 and HPV39. In this study of HPV in the microenvironment of penile precancerous lesions, we identified identical high-risk HPV genotypes in PeIN and classical, flat, or atypical condylomas and, specially, in nonspecific flat lesions with mild atypia. It is possible that some of these lesions represent hitherto unrecognized precancerous lesions.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, Netherlands
| | | |
Collapse
|
35
|
Smorra C, Stadnik YV, Blessing PE, Bohman M, Borchert MJ, Devlin JA, Erlewein S, Harrington JA, Higuchi T, Mooser A, Schneider G, Wiesinger M, Wursten E, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Yamazaki Y, Budker D, Ulmer S. Direct limits on the interaction of antiprotons with axion-like dark matter. Nature 2019; 575:310-314. [DOI: 10.1038/s41586-019-1727-9] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Accepted: 09/20/2019] [Indexed: 11/09/2022]
|
36
|
Glazov DA, Köhler-Langes F, Volotka AV, Blaum K, Heiße F, Plunien G, Quint W, Rau S, Shabaev VM, Sturm S, Werth G. g Factor of Lithiumlike Silicon: New Challenge to Bound-State QED. Phys Rev Lett 2019; 123:173001. [PMID: 31702246 DOI: 10.1103/physrevlett.123.173001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 08/31/2019] [Indexed: 06/10/2023]
Abstract
The recently established agreement between experiment and theory for the g factors of lithiumlike silicon and calcium ions manifests the most stringent test of the many-electron bound-state quantum electrodynamics (QED) effects in the presence of a magnetic field. In this Letter, we present a significant simultaneous improvement of both theoretical g_{th}=2.000 889 894 4 (34) and experimental g_{exp}=2.000 889 888 45 (14) values of the g factor of lithiumlike silicon ^{28}Si^{11+}. The theoretical precision now is limited by the many-electron two-loop contributions of the bound-state QED. The experimental value is accurate enough to test these contributions on a few percent level.
Collapse
Affiliation(s)
- D A Glazov
- Department of Physics, St. Petersburg State University, Universitetskaya 7/9, 199034 St. Petersburg, Russia
| | - F Köhler-Langes
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - A V Volotka
- Department of Physics, St. Petersburg State University, Universitetskaya 7/9, 199034 St. Petersburg, Russia
- Helmholtz-Institut Jena, Fröbelstieg 3, D-07743 Jena, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, D-64291 Darmstadt, Germany
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - F Heiße
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, D-64291 Darmstadt, Germany
| | - G Plunien
- Institut für Theoretische Physik, Technische Universität Dresden, Mommsenstraße 13, D-01062 Dresden, Germany
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, D-64291 Darmstadt, Germany
| | - S Rau
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - V M Shabaev
- Department of Physics, St. Petersburg State University, Universitetskaya 7/9, 199034 St. Petersburg, Russia
| | - S Sturm
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, D-69117 Heidelberg, Germany
| | - G Werth
- Institut für Physik, Johannes Gutenberg-Universität, D-55099 Mainz, Germany
| |
Collapse
|
37
|
Wagner S, Roberson D, Boland J, Kreimer AR, Yeager M, Cullen M, Mirabello L, Dunn ST, Walker J, Zuna R, Porras C, Cortes B, Sampson J, Herrero R, Rodriguez AC, Quint W, Van Doorn LJ, Hildesheim A, Schiffman M, Wentzensen N. Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. J Infect Dis 2019; 220:1609-1619. [PMID: 31536132 PMCID: PMC6782103 DOI: 10.1093/infdis/jiz324] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 06/25/2019] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Human papillomaviruses (HPV) cause over 500 000 cervical cancers each year, most of which occur in low-resource settings. Human papillomavirus genotyping is important to study natural history and vaccine efficacy. We evaluated TypeSeq, a novel, next-generation, sequencing-based assay that detects 51 HPV genotypes, in 2 large international epidemiologic studies. METHODS TypeSeq was evaluated in 2804 cervical specimens from the Study to Understand Cervical Cancer Endpoints and Early Determinants (SUCCEED) and in 2357 specimens from the Costa Rica Vaccine Trial (CVT). Positive agreement and risks of precancer for individual genotypes were calculated for TypeSeq in comparison to Linear Array (SUCCEED). In CVT, positive agreement and vaccine efficacy were calculated for TypeSeq and SPF10-LiPA. RESULTS We observed high overall and positive agreement for most genotypes between TypeSeq and Linear Array in SUCCEED and SPF10-LiPA in CVT. There was no significant difference in risk of precancer between TypeSeq and Linear Array in SUCCEED or in estimates of vaccine efficacy between TypeSeq and SPF10-LiPA in CVT. CONCLUSIONS The agreement of TypeSeq with Linear Array and SPF10-LiPA, 2 well established standards for HPV genotyping, demonstrates its high accuracy. TypeSeq provides high-throughput, affordable HPV genotyping for world-wide studies of cervical precancer risk and of HPV vaccine efficacy.
Collapse
Affiliation(s)
- Sarah Wagner
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Maryland
| | - David Roberson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Maryland
| | - Joseph Boland
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Maryland
| | - Aimée R Kreimer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Meredith Yeager
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Maryland
| | - Michael Cullen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Maryland
| | - Lisa Mirabello
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - S Terence Dunn
- University of Oklahoma Health Sciences Center, Oklahoma City
| | - Joan Walker
- University of Oklahoma Health Sciences Center, Oklahoma City
| | - Rosemary Zuna
- University of Oklahoma Health Sciences Center, Oklahoma City
| | - Carolina Porras
- Agencia Costarricense de Investigaciones Biomedicas, San José, Costa Rica
| | - Bernal Cortes
- Agencia Costarricense de Investigaciones Biomedicas, San José, Costa Rica
| | - Joshua Sampson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Rolando Herrero
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | | | - Allan Hildesheim
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| |
Collapse
|
38
|
Floore A, Hesselink A, Oštrbenk A, Alcaniz E, Rothe B, Pedersen H, Torres Hortal M, Doorn S, Quint W, Petry KU, Poljak M, Cuschieri K, Bonde J, de Sanjosé S, Bleeker M, Heideman D. Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study. J Clin Lab Anal 2019; 33:e22854. [PMID: 30758084 PMCID: PMC6528594 DOI: 10.1002/jcla.22854] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 11/29/2018] [Accepted: 12/21/2018] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND HPV-based cervical screening detects women at an increased risk of cervical cancer and precancer. To differentiate among HPV-positive women those with (pre)cancer, triage testing is necessary. The detection of cancer-associated host-cell DNA methylation (FAM19A4 and hsa-mir124-2) in cervical samples has shown valuable as triage test. This multicenter study from 6 collaborating European laboratories and one reference laboratory was set out to determine the intra- and inter-laboratory agreement of FAM19A4/mir124-2 DNA methylation analysis utilizing the QIAsure Methylation Test. METHODS Agreement analysis for the QIAsure Methylation Test was assessed on high-risk HPV-positive cervical specimens (n = 1680) both at the level of the assay and at the full workflow, including bisulfite conversion. RESULTS Intra- and inter-laboratory assay agreement were 91.4% (534/584; 95% CI 88.9-93.5; κ = 0.82) and 92.5% (369/399; 95% CI 90.0-94.7; κ = 0.83), respectively. The inter-laboratory workflow (bisulfite conversion and assay combined) agreement was 90.0% (627/697; 95% CI 87.5%-92.0%; κ = 0.76). CONCLUSION These data show that the QIAsure Methylation Test performs robust and reproducible in different laboratory contexts. These results support the use of the QIAsure Methylation Test for full molecular screening for cervical cancer, including primary HPV testing and triage testing by methylation analysis.
Collapse
Affiliation(s)
| | | | - Anja Oštrbenk
- Institute of Microbiology and immunology, University of Ljubljana, Ljubljana, Slovenia
| | - Elia Alcaniz
- HPV Research Group, Division of Pathology, University of Edinburgh, Edinburgh, Scotland
| | - Beate Rothe
- Institute for clinical chemistry, laboratory and transfusion medicine, Wolfsburg, Germany
| | - Helle Pedersen
- Molecular Pathology Laboratory, Department of Pathology, Hvidovre Hospital, Hvidovre, Denmark
| | | | | | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, the Netherlands
| | - Karl Ulrich Petry
- Institute for clinical chemistry, laboratory and transfusion medicine, Wolfsburg, Germany
| | - Mario Poljak
- Institute of Microbiology and immunology, University of Ljubljana, Ljubljana, Slovenia
| | - Kate Cuschieri
- HPV Research Group, Division of Pathology, University of Edinburgh, Edinburgh, Scotland
| | - Jesper Bonde
- Molecular Pathology Laboratory, Department of Pathology, Hvidovre Hospital, Hvidovre, Denmark
| | - Silvia de Sanjosé
- Infections and Cancer Laboratory, Catalan Institute of Oncology (ICO), Barcelona, Spain
| | - Maaike Bleeker
- Amsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Cancer Center Amsterdam, Amsterdam, the Netherlands
| | - Daniëlle Heideman
- Amsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Cancer Center Amsterdam, Amsterdam, the Netherlands
| |
Collapse
|
39
|
Borchert MJ, Blessing PE, Devlin JA, Harrington JA, Higuchi T, Morgner J, Smorra C, Wursten E, Bohman M, Wiesinger M, Mooser A, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Yamazaki Y, Ulmer S. Measurement of Ultralow Heating Rates of a Single Antiproton in a Cryogenic Penning Trap. Phys Rev Lett 2019; 122:043201. [PMID: 30768304 DOI: 10.1103/physrevlett.122.043201] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Indexed: 06/09/2023]
Abstract
We report on the first detailed study of motional heating in a cryogenic Penning trap using a single antiproton. Employing the continuous Stern-Gerlach effect we observe cyclotron quantum transition rates of 6(1) quanta/h and an electric-field noise spectral density below 7.5(3.4)×10^{-20} V^{2} m^{-2} Hz^{-1}, which corresponds to a scaled noise spectral density below 8.8(4.0)×10^{-12} V^{2} m^{-2}, results which are more than 2 orders of magnitude smaller than those reported by other ion-trap experiments.
Collapse
Affiliation(s)
- M J Borchert
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
- Institut für Quantenoptik, Leibniz Universität Hannover, 30167 Hannover, Germany
| | - P E Blessing
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
- GSI-Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - J A Devlin
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
| | - J A Harrington
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - T Higuchi
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
- Graduate School of Arts and Sciences, University of Tokyo, Tokyo 153-8902, Japan
| | - J Morgner
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
- Institut für Quantenoptik, Leibniz Universität Hannover, 30167 Hannover, Germany
| | - C Smorra
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
| | - E Wursten
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
- CERN, 1211 Geneva 23, Switzerland
| | - M Bohman
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - M Wiesinger
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Mooser
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
| | - K Blaum
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - Y Matsuda
- Graduate School of Arts and Sciences, University of Tokyo, Tokyo 153-8902, Japan
| | - C Ospelkaus
- Institut für Quantenoptik, Leibniz Universität Hannover, 30167 Hannover, Germany
- Physikalisch-Technische Bundesanstalt, 38116 Braunschweig, Germany
| | - W Quint
- GSI-Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Ruprecht-Karls-Universität Heidelberg, 69047 Heidelberg, Germany
| | - J Walz
- Institut für Physik, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
- Helmholtz-Institut Mainz, 55099 Mainz, Germany
| | - Y Yamazaki
- Atomic Physics Laboratory, RIKEN, Wako, Saitama 351-0198, Japan
| | - S Ulmer
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
| |
Collapse
|
40
|
Pirog EC, Park KJ, Kiyokawa T, Zhang X, Chen W, Jenkins D, Quint W. Gastric-type Adenocarcinoma of the Cervix: Tumor With Wide Range of Histologic Appearances. Adv Anat Pathol 2019; 26:1-12. [PMID: 30234500 DOI: 10.1097/pap.0000000000000216] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Gastric-type endocervical adenocarcinoma (GAS) is a recently described diagnostic entity originally characterized as a tumor with (1) voluminous cytoplasm that is (2) clear or pale eosinophilic, and (3) cells showing distinct cell borders. Since the initial tumor description there has been accumulating experience that the neoplasm, in addition to classic features, may show a wide spectrum of morphologic appearances. This paper describes and illustrates cases of GAS with focal or diffuse findings that include: densely eosinophilic cytoplasm, foamy cytoplasm, goblet cells, glands with elongated, stratified nuclei, glands with small cuboidal cells, glands with flattened cells, papillary growth, single cell infiltration and infiltration with microcystic elongated and fragmented pattern. All these patterns may bring up a differential diagnosis with other cervical malignancies such as usual, intestinal, endometrioid, clear cell, serous, and mesonephric adenocarcinoma. The paper describes the patterns of immunostaining of respective lesions that may aid in the diagnostic process and summarizes the main points of the differential diagnosis. GAS is associated with somatic and germline STK11 mutations and TP53 mutations but is invariably negative for human papilloma virus when tumor only is tested. It shows variation in incidence between countries. Awareness of the spectrum of morphologic appearances in GAS is important for accurate and confident diagnosis. Correct identification of GAS is important due to its propensity for ovarian and other distant metastases, markedly worse prognosis as compared with usual endocervical adenocarcinoma, and its relative resistance to chemotherapy.
Collapse
|
41
|
Pimenoff VN, Tous S, Benavente Y, Alemany L, Quint W, Bosch FX, Bravo IG, de Sanjosé S. Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: Results from a worldwide cross-sectional study. Int J Cancer 2018; 144:2478-2488. [PMID: 30387873 DOI: 10.1002/ijc.31964] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 10/01/2018] [Accepted: 10/16/2018] [Indexed: 01/10/2023]
Abstract
Coinfections by multiple Human Papillomaviruses (HPVs) are observed in approximately 6-8% of invasive cervical cancer (ICC) cases worldwide. But neither the presence of persistent HPVs coinfections nor their etiological role in the development of ICC is well understood. Cervical HPVs coinfections have been observed randomly, mostly in women with preneoplastic lesions, and only few studies have globally analyzed ICC cases. Here we explored the HPVs multiple infection patterns in a large worldwide sample of cross-sectional ICC cases. Paraffin-embedded ICC biopsy samples were tested using stringent HPV genotyping. Logistic regression models were used to identify the most likely pairwise HPV types in multiple infections. Multivariate analysis was applied to detect significant HPV coinfection patterns beyond pairwise HPVs comparison. Among 8780 HPV DNA-positive ICC cases worldwide, 6.7% (N = 587) contained multiple HPVs. Pairwise analysis revealed that HPV16|74, HPV31|33, HPV31|44, HPV33|44 and HPV45|70 pairs were significantly more frequently found together in multiple infections compared to any other HPV type combination, which supports the occasional role of Alpha-10 LR-HPVs in cervical cancers. In contrast, HPV16|31, HPV16|45, HPV16|51 and HPV18|HPV45 pairs were significantly less frequently found together than with any other HPV pair combination. Multivariate analysis sustained the results and revealed for the first time a distinct coinfection pattern in African ICCs stemming from the clustering of oncogenic HPV51/35/18/52 coinfections in African women. We suggest that the differential geographic HPVs coinfections clustering observed might be compatible with a specific modulation of the natural history/oncogenic potential of particular HPVs multiple infections and warrant monitoring for post-vaccinated.
Collapse
Affiliation(s)
- Ville N Pimenoff
- Unit of Biomarkers and Susceptibility, Bellvitge Institute of Biomedical Research (IDIBELL), Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Epidemiology, University of Tampere, Tampere, Finland
| | - Sara Tous
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Yolanda Benavente
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain.,CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Laia Alemany
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain.,CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | - Francesc Xavier Bosch
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Ignacio G Bravo
- National Center for Scientific Research (CNRS), Laboratory MIVEGEC (UMR CNRS, IRD, UM), Montpellier, France
| | - Silvia de Sanjosé
- Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain.,CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,PATH, Reproductive Health Global Program, Seattle, USA
| |
Collapse
|
42
|
Leeman A, Del Pino M, Molijn A, Rodriguez A, Torné A, de Koning M, Ordi J, van Kemenade F, Jenkins D, Quint W. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population. BJOG 2018; 124:1356-1363. [PMID: 28391609 DOI: 10.1111/1471-0528.14682] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2017] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To compare the sensitivity of high-risk human papillomavirus (hrHPV) and genotype detection in self-collected urine samples in the morning (U1), and later on (U2), brush-based self-samples (SS), and clinician-taken smears (CTS) for detecting cervical intraepithelial neoplasia grade 2+ (CIN2+) in a colposcopic referral population. DESIGN Cross-sectional single-centre study. SETTING A colposcopy clinic in Spain. POPULATION A cohort of 113 women referred for colposcopy after an abnormal Pap smear. METHODS Women undergoing colposcopy with biopsy for abnormal Pap smears were sent a device (Colli-Pee™, Novosanis, Wijnegem, Belgium) to collect U1 on the morning of colposcopy. U2, CTS, and SS (Evalyn brush™, Rovers Medical Devices B.V., Oss, the Netherlands) were also analysed. All samples were tested for HPV DNA using the analytically sensitive SPF10-DEIA-LiPA25 assay and the clinically validated GP5+/6+-EIA-LMNX. MAIN OUTCOME MEASURES Histologically confirmed CIN2+ and hrHPV positivity for 14 high-risk HPV types. RESULTS Samples from 91 patients were analysed. All CIN3 cases (n = 6) tested positive for hrHPV in CTS, SS, U1, and U2 with both HPV assays. Sensitivity for CIN2+ with the SPF10 system was 100, 100, 95, and 100%, respectively. With the GP5+/6+ assay, sensitivity was 95% in all sample types. The sensitivities and specificities for both tests on each of the sample types did not significantly differ. There was 10-14% discordance on hrHPV genotype. CONCLUSIONS CIN2+ detection using HPV testing of U1 shows a sensitivity similar to that of CTS or brush-based SS, and is convenient. There was substantial to almost excellent agreement between all samples on genotype with both hrHPV assays. There was no advantage in testing U1 compared with U2 samples. TWEETABLE ABSTRACT Similar CIN2+ sensitivity for HPV testing in first-void urine, physician-taken smear and brush-based self-sample.
Collapse
Affiliation(s)
- A Leeman
- DDL Diagnostic Laboratory, ER Rijswijk, the Netherlands
| | - M Del Pino
- Faculty of Medicine-University 9 of Barcelona, Institute of Gynaecology, Obstetrics and Neonatology, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I 8 Sunyer (IDIBAPS), Barcelona, Spain
| | - A Molijn
- DDL Diagnostic Laboratory, ER Rijswijk, the Netherlands
| | - A Rodriguez
- Faculty of Medicine-University 9 of Barcelona, Institute of Gynaecology, Obstetrics and Neonatology, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I 8 Sunyer (IDIBAPS), Barcelona, Spain
| | - A Torné
- Faculty of Medicine-University 9 of Barcelona, Institute of Gynaecology, Obstetrics and Neonatology, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi I 8 Sunyer (IDIBAPS), Barcelona, Spain
| | - M de Koning
- DDL Diagnostic Laboratory, ER Rijswijk, the Netherlands
| | - J Ordi
- Department of Pathology, ISGLobal 11 (Institut de Salit Global de Barcelona)-Hospital Clínic, Barcelona, Spain
| | - F van Kemenade
- Department of Pathology, Erasmus Medical Centre, CA Rotterdam, the Netherlands
| | - D Jenkins
- DDL Diagnostic Laboratory, ER Rijswijk, the Netherlands
| | - W Quint
- DDL Diagnostic Laboratory, ER Rijswijk, the Netherlands
| |
Collapse
|
43
|
de Sanjosé S, Serrano B, Tous S, Alejo M, Lloveras B, Quirós B, Clavero O, Vidal A, Ferrándiz-Pulido C, Pavón MÁ, Holzinger D, Halec G, Tommasino M, Quint W, Pawlita M, Muñoz N, Bosch FX, Alemany L. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr 2018; 2:pky045. [PMID: 31360870 PMCID: PMC6649711 DOI: 10.1093/jncics/pky045] [Citation(s) in RCA: 97] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 07/14/2018] [Accepted: 07/27/2018] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. METHODS In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. RESULTS The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. CONCLUSIONS Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Collapse
Affiliation(s)
- Silvia de Sanjosé
- Cancer Epidemiology Research Program, ICO; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (SDS, BS, ST, BQ, OC, MAP, FXB, LA)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- PATH, Scale-Up Project Director, Sexual and Reproductive Health Global Program
| | - Beatriz Serrano
- Cancer Epidemiology Research Program, ICO; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (SDS, BS, ST, BQ, OC, MAP, FXB, LA)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Sara Tous
- Cancer Epidemiology Research Program, ICO; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (SDS, BS, ST, BQ, OC, MAP, FXB, LA)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Maria Alejo
- Department of Pathology, Hospital General de l'Hospitalet, Av. Josep Molins, 29, 08906 L’Hospitalet de Llobregat, Barcelona, Spain
| | - Belén Lloveras
- Department of Pathology, Hospital del Mar, Passeig Marítim, 25–29, 08003 Barcelona, Spain
| | - Beatriz Quirós
- Cancer Epidemiology Research Program, ICO; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (SDS, BS, ST, BQ, OC, MAP, FXB, LA)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Omar Clavero
- Cancer Epidemiology Research Program, ICO; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (SDS, BS, ST, BQ, OC, MAP, FXB, LA)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - August Vidal
- Department of Pathology, Hospital Universitari de Bellvitge, Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
| | - Carla Ferrándiz-Pulido
- Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119–129, 08035 Barcelona, Spain
| | - Miquel Ángel Pavón
- Cancer Epidemiology Research Program, ICO; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (SDS, BS, ST, BQ, OC, MAP, FXB, LA)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Dana Holzinger
- Division of Molecular Diagnostics of Oncogenic Infections, Research Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), ImNeuenheimer Feld 280, 69120 Heidelberg, Germany
| | - Gordana Halec
- Division of Molecular Diagnostics of Oncogenic Infections, Research Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), ImNeuenheimer Feld 280, 69120 Heidelberg, Germany
- Obstetrics and Gynecology Department, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-7363, USA
| | - Massimo Tommasino
- Infections and Cancer Biology Group, IARC, WHO, 150 Cours Albert Thomas, 69008 Lyon, France
| | - Wim Quint
- DDL Diagnostic Laboratory, Visseringlaan 25, 2288 ER Rijswijk, Netherlands
| | - Michael Pawlita
- Division of Molecular Diagnostics of Oncogenic Infections, Research Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), ImNeuenheimer Feld 280, 69120 Heidelberg, Germany
| | - Nubia Muñoz
- National Cancer Institute of Colombia, Calle 1 No. 9–85, Bogota, Colombia
| | - Francesc Xavier Bosch
- Cancer Epidemiology Research Program, ICO; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (SDS, BS, ST, BQ, OC, MAP, FXB, LA)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Laia Alemany
- Cancer Epidemiology Research Program, ICO; Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet, 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (SDS, BS, ST, BQ, OC, MAP, FXB, LA)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| |
Collapse
|
44
|
Alejo M, Alemany L, Clavero O, Quiros B, Vighi S, Seoud M, Cheng-Yang C, Garland SM, Juanpere N, Lloreta J, Tous S, Klaustermeier JE, Quint W, Bosch FX, de Sanjosé S, Lloveras B. Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases. Papillomavirus Res 2018; 5:134-142. [PMID: 29555602 PMCID: PMC5909066 DOI: 10.1016/j.pvr.2018.03.005] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Revised: 03/12/2018] [Accepted: 03/15/2018] [Indexed: 12/24/2022]
Abstract
Aims Neuroendocrine tumors (NET) of the cervix are rare tumors with a very aggressive course. The human papillomavirus (HPV) has been linked to its etiology. The objective of this study is to describe HPV prevalence and genotype distribution of NET. Methods and Results Forty-nine tumors with histological neuroendocrine features were identified among 10,575 invasive cervical cancer (ICC) cases from an international study. HPV DNA detection was done using SPF10/DEIA /LiPA25 system. Immunohistochemical (IHC) staining for neuroendocrine markers (chromogranin A, synaptophysin, CD56) and for p16INK4a as a surrogate for HPV transforming infection was performed. In 13 samples with negative IHC for all 3 neuroendocrine markers studied, it was possible to conduct electron microscopy (EM). NET represented 0.5% of the total ICC series and HPV was detected in 42 out of 49 samples (85.7%, 95%CI:72.8%,94.1%). HPV16 was the predominant type (54.8%), followed by HPV18 (40.5%). p16INK4a overexpression was observed in 38/44 cases (86.4%). Neuroendocrine IHC markers could be demonstrated in 24/37 (64.9%) cases. EM identified neuroendocrine granules in 8 samples with negative IHC markers. Conclusions Our data confirms the association of cervical NET with HPV and p16INK4a overexpression. Specifically, HPV16 and 18 accounted together for over 95% of the HPV positive cases. Current HPV vaccines could largely prevent these aggressive tumors. Neuroendocrine tumors of the cervix are rare tumors with aggressive course. We identified HPV DNA in 85.7% of neuroendocrine tumors analyzed. HPV16 and 18 accounted together for over 95% of the HPV DNA positive cases.
Collapse
Affiliation(s)
- Maria Alejo
- Hospital General de l'Hospitalet, Consorci Sanitari Integral, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Laia Alemany
- Infections and Cancer Unit, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia (ICO)-IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERESP), Madrid, Spain
| | - Omar Clavero
- Infections and Cancer Unit, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia (ICO)-IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
| | - Beatriz Quiros
- Infections and Cancer Unit, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia (ICO)-IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Susana Vighi
- Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Muhieddine Seoud
- The American University of Beirut Medical Center, Beirut, Lebanon
| | - Chou Cheng-Yang
- National Cheng Kung University Medical College, Taiwan Association of Gynecologic Oncologists, Tainan, Taiwan
| | - Suzanne M Garland
- The Royal Women's Hospital, The University of Melbourne, Melbourne, Australia
| | | | - Josep Lloreta
- Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
| | - Sara Tous
- Infections and Cancer Unit, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia (ICO)-IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Jo Ellen Klaustermeier
- Infections and Cancer Unit, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia (ICO)-IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain
| | - Wim Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
| | - F Xavier Bosch
- Infections and Cancer Unit, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia (ICO)-IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Silvia de Sanjosé
- Infections and Cancer Unit, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia (ICO)-IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERESP), Madrid, Spain
| | | |
Collapse
|
45
|
Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, Schiller J, Schiffman MT, Rodriguez AC, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Kreimer AR. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. J Natl Cancer Inst 2018; 110:4096545. [PMID: 28954299 PMCID: PMC6075614 DOI: 10.1093/jnci/djx158] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 05/02/2017] [Accepted: 06/30/2017] [Indexed: 01/16/2023] Open
Abstract
Background Previously, we demonstrated similar human papillomavirus (HPV)16/18 vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination in a nonrandomized analysis of women who received a varying number of doses of the bivalent HPV16/18 vaccine. Here we extend data to seven years following initial vaccination. Methods We evaluated HPV16/18-vaccinated women who received one (n = 134), two (n 0/1 = 193, n 0/6 = 79), or three doses (n = 2043) to a median of 6.9 years postvaccination. Cervical HPV DNA was measured with the SPF10- DEIA-LiPA PCR system; HPV16/18-specific antibody levels were measured using enzyme-linked immunosorbent assays (n = 486). Infection and immunological measures were compared across vaccine dose groups. Prevalent HPV infection at year 7 was also compared with an unvaccinated control group (UCG). All statistical tests were two-sided. Results Among women in the three-dose, two-dose 0/6 , two-dose 0/1 , and one-dose groups, cumulative incident HPV16/18 infection rates (No. of events/No. of individuals) were 4.3% (88/2036, 95% confidence interval [CI] = 3.5% to 5.3%), 3.8% (3/78, 95% CI = 1.0% to 10.1%), 3.6% (7/192, 95% CI = 1.6% to 7.1%), and 1.5% (2/133, 95% CI = 0.3% to 4.9%; P = 1.00, .85, .17 comparing the two-dose 0/6 , two-dose 0/1 , and one-dose groups to the three-dose group, respectively). The prevalence of other carcinogenic and noncarcinogenic HPV types, excluding HPV16/18/31/33/45, were high and not statistically different among all dose groups, indicating that the low incidence of HPV16/18 in the one- and two-dose groups was not due to lack of exposure. At seven years, 100% of participants in all dose groups remained HPV16 and HPV18 seropositive. A non-statistically significant decrease in the geometric mean of the HPV16 antibody levels between years 4 and 7 was observed among women in the three-dose group: -10.8% (95% CI = -25.3% to 6.6%); two-dose (0/6 months) group: -17.3% (95% CI = -39.3% to 12.8%), two-dose (0/1 month) group: -6.9% (95% CI = -22.1% to 11.2%), and one-dose group: -5.5% (95% CI = -29.7% to 27.0%); results were similar for HPV18. Conclusions At an average of seven years of follow-up, we observed similar low rates of HPV16/18 infections and slight, if any, decreases in HPV16/18 antibody levels by dose group.
Collapse
Affiliation(s)
| | - Joshua N. Sampson
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Yuanji Pan
- HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Carolina Porras
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica
| | - Troy J. Kemp
- HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Rolando Herrero
- Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France
| | - Wim Quint
- DDL, Diagnostic Laboratory, Rijswijk, the Netherlands
| | | | | | - Douglas R. Lowy
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - John Schiller
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Mark T. Schiffman
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Ana Cecilia Rodriguez
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica
- Independent Consultant, San José, Costa Rica
| | - Mitchell H. Gail
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Allan Hildesheim
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Paula Gonzalez
- Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica
| | - Ligia A. Pinto
- HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Aimée R. Kreimer
- National Cancer Institute, National Institutes of Health, Bethesda, MD
| |
Collapse
|
46
|
Wiesel M, Birkl G, Ebrahimi MS, Martin A, Quint W, Stallkamp N, Vogel M. Optically transparent solid electrodes for precision Penning traps. Rev Sci Instrum 2017; 88:123101. [PMID: 29289211 DOI: 10.1063/1.5002180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
We have conceived, built, and operated a cryogenic Penning trap with an electrically conducting yet optically transparent solid electrode. The trap, dedicated to spectroscopy and imaging of confined particles under large solid angles, is of "half-open" design with one open endcap and one closed endcap that mainly consists of a glass window coated with a highly transparent conductive layer. This arrangement allows for the trapping of externally or internally produced particles and yields flexible access for optical excitation and efficient light collection from the trapping region. At the same time, it is electrically closed and ensures long-term ion confinement under well-defined conditions. With its superior surface quality and its high as well as homogeneous optical transmission, the window electrode is an excellent replacement for partially transmissive electrodes that use holes, slits, metallic meshes, and the like.
Collapse
Affiliation(s)
- M Wiesel
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - G Birkl
- Institut für Angewandte Physik, TU Darmstadt, 64291 Darmstadt, Germany
| | - M S Ebrahimi
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - A Martin
- Institut für Angewandte Physik, TU Darmstadt, 64291 Darmstadt, Germany
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - N Stallkamp
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - M Vogel
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| |
Collapse
|
47
|
Smorra C, Sellner S, Borchert MJ, Harrington JA, Higuchi T, Nagahama H, Tanaka T, Mooser A, Schneider G, Bohman M, Blaum K, Matsuda Y, Ospelkaus C, Quint W, Walz J, Yamazaki Y, Ulmer S. A parts-per-billion measurement of the antiproton magnetic moment. Nature 2017; 550:371-374. [DOI: 10.1038/nature24048] [Citation(s) in RCA: 82] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Accepted: 08/30/2017] [Indexed: 11/10/2022]
|
48
|
Rakislova N, Clavero O, Alemany L, Saco A, Quirós B, Lloveras B, Alejo M, Pawlita M, Quint W, del Pino M, de Sanjose S, Ordi J. "Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A study of 1,594 cases”. Int J Cancer 2017; 141:2517-2527. [DOI: 10.1002/ijc.31006] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Revised: 08/03/2017] [Accepted: 08/07/2017] [Indexed: 12/17/2022]
Affiliation(s)
- Natalia Rakislova
- Department of Pathology; ISGlobal, Hospital Clínic - Universitat de Barcelona; Barcelona Spain
| | - Omar Clavero
- Unit of Infections and Cancer; Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat; Barcelona Spain
| | - Laia Alemany
- Unit of Infections and Cancer; Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat; Barcelona Spain
- CIBER Epidemiologia y Salud Pública; Barcelona Spain
| | - Adela Saco
- Department of Pathology; ISGlobal, Hospital Clínic - Universitat de Barcelona; Barcelona Spain
| | - Beatriz Quirós
- Unit of Infections and Cancer; Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat; Barcelona Spain
| | - Belen Lloveras
- Department of Pathology; Hospital del Mar; Barcelona Spain
| | - Maria Alejo
- Department of Pathology; Hospital General d'Hospitalet, L'Hospitalet de LLobregat; Barcelona Spain
| | - Michael Pawlita
- Division of Molecular Diagnostics of Oncogenic Infections, Research Program Infection, Inflammation and Cancer; German Cancer Research Center (DKFZ); Heidelberg Germany
| | - Wim Quint
- DDL Diagnostic Laboratory; Rijswijk The Netherlands
| | - Marta del Pino
- Faculty of Medicine, Institute of Gynecology, Obstetrics and Neonatology, Hospital Clínic - Institut d´Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona; Barcelona Spain
| | - Silvia de Sanjose
- Unit of Infections and Cancer; Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat; Barcelona Spain
- CIBER Epidemiologia y Salud Pública; Barcelona Spain
| | - Jaume Ordi
- Department of Pathology; ISGlobal, Hospital Clínic - Universitat de Barcelona; Barcelona Spain
| | | |
Collapse
|
49
|
Heiße F, Köhler-Langes F, Rau S, Hou J, Junck S, Kracke A, Mooser A, Quint W, Ulmer S, Werth G, Blaum K, Sturm S. High-Precision Measurement of the Proton's Atomic Mass. Phys Rev Lett 2017; 119:033001. [PMID: 28777624 DOI: 10.1103/physrevlett.119.033001] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2017] [Indexed: 06/07/2023]
Abstract
We report on the precise measurement of the atomic mass of a single proton with a purpose-built Penning-trap system. With a precision of 32 parts per trillion our result not only improves on the current CODATA literature value by a factor of 3, but also disagrees with it at a level of about 3 standard deviations.
Collapse
Affiliation(s)
- F Heiße
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - F Köhler-Langes
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - S Rau
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - J Hou
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - S Junck
- Institut für Physik, Johannes Gutenberg-Universität, 55099 Mainz, Germany
| | - A Kracke
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - A Mooser
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
| | - W Quint
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - S Ulmer
- RIKEN, Ulmer Fundamental Symmetries Laboratory, Wako, Saitama 351-0198, Japan
| | - G Werth
- Institut für Physik, Johannes Gutenberg-Universität, 55099 Mainz, Germany
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - S Sturm
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| |
Collapse
|
50
|
Beachler DC, Kuhs KAL, Struijk L, Schussler J, Herrero R, Porras C, Hildesheim A, Cortes B, Sampson J, Quint W, Gonzalez P, Kreimer AR. The Natural History of Oral Human Papillomavirus in Young Costa Rican Women. Sex Transm Dis 2017; 44:442-449. [PMID: 28608796 PMCID: PMC6299456 DOI: 10.1097/olq.0000000000000625] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Oral human papillomavirus (HPV) infection and related oropharyngeal cancer are uncommon in lower-income countries, particularly compared to HPV-associated cervical cancer. However, little is known about the natural history of oral HPV in less-developed settings and how it compares to the natural history of cervical HPV. METHODS Three hundred fifty women aged 22 to 33 years from the Costa Rica Vaccine Trial provided exfoliated cells from the cervical and oral regions at 2 visits 2 years apart. Samples from both visits were tested for 25 characterized α HPV types by the SPF10 PCR-DNA enzyme immunoassay-LiPA25 version 1 system. Risk factors for oral HPV persistence were calculated utilizing generalized estimating equations with a logistic link. RESULTS Among the 82 women with characterized α oral HPV DNA detected at baseline, 14 persisted and were detected 2 years later (17.6%; 95% confidence interval [CI], 10.9-28.5%) and was similar to the persistence of α cervical HPV (40/223; 17.7%; 95% CI, 13.1-23.9%; P = 0.86). Acquisition of new α oral HPV type was low; incident infection (1.7%; 95% CI, 0.6-3.7%). CONCLUSIONS Oral HPV DNA is uncommon in young women in Latin America, and often appears to clear within a few years at similar rates to cervical HPV.
Collapse
Affiliation(s)
- Daniel C. Beachler
- Division of Cancer Epidemiology, and Genetics, National Cancer Institute, NIH, Bethesda, MD
| | - Krystle A. Lang Kuhs
- Division of Cancer Epidemiology, and Genetics, National Cancer Institute, NIH, Bethesda, MD
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Linda Struijk
- DDL Diagnostic Laboratory, Voorburg, the Netherlands
| | | | | | - Carolina Porras
- Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Costa Rica
| | - Allan Hildesheim
- Division of Cancer Epidemiology, and Genetics, National Cancer Institute, NIH, Bethesda, MD
| | - Bernal Cortes
- Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Costa Rica
| | - Joshua Sampson
- Division of Cancer Epidemiology, and Genetics, National Cancer Institute, NIH, Bethesda, MD
| | - Wim Quint
- DDL Diagnostic Laboratory, Voorburg, the Netherlands
| | - Paula Gonzalez
- Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Costa Rica
| | - Aimée R. Kreimer
- Division of Cancer Epidemiology, and Genetics, National Cancer Institute, NIH, Bethesda, MD
| |
Collapse
|